AdaptHealth (AHCO) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 02, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	001-38399
Entity Registrant Name	AdaptHealth Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3677704
Entity Address, Address Line One	220 West Germantown Pike
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	610
Local Phone Number	630-6357
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AHCO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		130,910,675
Entity Central Index Key	0001725255
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 178,189	$ 99,962
Accounts receivable	302,127	171,065
Inventory	81,507	58,783
Prepaid and other current assets	29,046	33,441
Total current assets	590,869	363,251
Equipment and other fixed assets, net	309,071	110,468
Goodwill	3,231,200	998,810
Identifiable intangible assets, net	233,630	116,061
Other assets	19,344	16,483
Deferred tax assets	303,551	208,399
Total Assets	4,687,665	1,813,472
Current liabilities:
Accounts payable and accrued expenses	350,714	254,212
Current portion of capital lease obligations	23,919	22,282
Current portion of long-term debt	96,750	8,146
Contract liabilities	24,872	11,043
Other liabilities	83,861	89,524
Contingent consideration common shares liability	25,758	36,846
Total current liabilities	605,874	422,053
Long-term debt, less current portion	1,776,326	776,568
Other long-term liabilities	317,464	186,470
Long term portion of contingent consideration common shares liability	20,675	33,631
Warrant liability	73,283	113,905
Total Liabilities	2,793,622	1,532,627
Commitments and contingencies (note 14)
Stockholders' Equity
Preferred Stock, par value of $0.0001 per share, 5,000,000 shares authorized; 124,060 and 163,560 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	2,015,875	558,486
Accumulated deficit	(124,055)	(199,196)
Accumulated other comprehensive loss	(1,871)	(4,411)
Total stockholders' equity attributable to AdaptHealth Corp.	1,889,963	354,889
Noncontrolling interest in subsidiaries	4,080	(74,044)
Total Stockholders' Equity	1,894,043	280,845
Total Liabilities and Stockholders' Equity	4,687,665	1,813,472
Class A Common Stock
Stockholders' Equity
Common stock	$ 13	8
Class B Common Stock
Stockholders' Equity
Common stock		$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	124,060	163,560
Preferred stock, shares outstanding (in shares)	124,060	0
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	210,000,000	210,000,000
Common stock, shares issued (in shares)	130,064,838	76,457,439
Common stock, shares outstanding (in shares)	130,064,838	76,457,439
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	35,000,000	35,000,000
Common stock, shares issued (in shares)	0	13,218,758
Common stock, shares outstanding (in shares)	0	13,218,758

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Net revenue	$ 617,017	$ 232,116	$ 1,099,136	$ 423,555
Revenue, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
Costs and expenses:
Cost of net revenue	$ 490,720	$ 198,418	$ 887,418	$ 366,048
Cost, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
General and administrative expenses	$ 42,946	$ 17,092	$ 99,578	$ 31,439
Depreciation and amortization, excluding patient equipment depreciation	17,944	1,036	31,324	2,278
Total costs and expenses	551,610	216,546	1,018,320	399,765
Operating income	65,407	15,570	80,816	23,790
Interest expense, net	23,147	7,482	45,332	15,420
Loss on extinguishment of debt	7,736		11,949
Change in fair value of contingent consideration - common shares liability	(22,079)	(42)	(24,044)	16,325
Change in fair value of warrant liability	(37,454)	(654)	(40,622)	35,446
Other loss (income), net	1,669	(900)	1,150	(1,991)
Income (loss) before income taxes	92,388	9,684	87,051	(41,410)
Income tax expense	12,330	1,826	10,635	185
Net income (loss)	80,058	7,858	76,416	(41,595)
Income (loss) attributable to noncontrolling interest	951	3,388	1,275	(11,514)
Net income (loss) attributable to AdaptHealth Corp.	$ 79,107	$ 4,470	$ 75,141	$ (30,081)
Weighted average shares outstanding
Basic	129,664	44,508	120,438	43,242
Diluted	136,582	47,834	127,720	43,242
Net income (loss) per common share:
Basic	$ 0.56	$ 0.10	$ 0.56	$ (0.70)
Diluted	$ 0.12	$ 0.08	$ 0.06	$ (0.70)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Consolidated Statements of Comprehensive Income (Loss)
Net income (loss)	$ 80,058	$ 7,858	$ 76,416	$ (41,595)
Other comprehensive income (loss):
Interest rate swap agreements, inclusive of reclassification adjustment	664	(1,066)	2,540	(12,483)
Comprehensive income (loss)	80,722	6,792	78,956	(54,078)
Income (loss) attributable to noncontrolling interests	951	3,388	1,275	(11,514)
Comprehensive income (loss) attributable to AdaptHealth Corp.	$ 79,771	$ 3,404	$ 77,681	$ (42,564)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Class A Common StockCommon StockPublic Offering [Member]	Class A Common StockCommon Stock	Class A Common StockAdditional paid-in capital	Class A Common Stock	Class B Common StockCommon Stock	Series C Preferred Stock [Member]Preferred Stock	Series C Preferred Stock [Member]Additional paid-in capital	Series C Preferred Stock [Member]	Preferred Stock	Additional paid-in capitalPublic Offering [Member]	Additional paid-in capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests in subsidiaries	Public Offering [Member]	Total
Balance at beginning of period at Dec. 31, 2019		$ 4			$ 3							$ (40,258)	$ 1,431	$ (26,963)		$ (65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019		40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions											$ 6,248					6,248
Issuance of stock for acquisitions (in shares)		387,000
Exchange of Class B Common Stock for Class A Common Stock											(361)			361
Exchange of Class B Common Stock for Class A Common Stock (in shares)		1,000,000			(1,000,000)
Exercise of warrants											15,273					15,273
Exercise of warrants (in shares)		1,092,000
Equity-based compensation											2,223					2,223
Equity-based compensation (in shares)		59,000
Net income (loss)												(34,551)		(14,902)		(49,453)
Equity activity resulting from Tax Receivable Agreement											2,483					2,483
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													(6,570)	(4,847)		(11,417)
Balance at end of period at Mar. 31, 2020		$ 4			$ 3						25,866	(74,809)	(5,139)	(46,351)		(100,426)
Shares, Outstanding, Ending Balance at Mar. 31, 2020		43,354,000			30,564,000
Balance at beginning of period at Dec. 31, 2019		$ 4			$ 3							(40,258)	1,431	(26,963)		(65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019		40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net income (loss)																(41,595)
Equity activity resulting from the Put/Call Agreement																(29,900)
Warrant liability adjustment																21,019
Balance at end of period at Jun. 30, 2020		$ 3			$ 3				$ 1		17,454	(70,339)	(5,795)	(42,593)		(101,266)
Shares, Outstanding, Ending Balance at Jun. 30, 2020		30,665,000			28,509,000				158,000
Balance at beginning of period at Dec. 31, 2019		$ 4			$ 3							(40,258)	1,431	(26,963)		$ (65,783)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019		40,816,000			31,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of Class A Common Stock in connection with Contingent Consideration Shares (in shares)																1,000,000
Equity impact resulting from the Put/Call Agreement (in shares)																(1,898,967)
Balance at end of period at Dec. 31, 2020		$ 8			$ 1				$ 1		558,486	(199,196)	(4,411)	(74,044)		$ 280,845
Shares, Outstanding, Ending Balance at Dec. 31, 2020		76,458,000			13,219,000				164,000
Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Distributions to noncontrolling interest														(800)		(800)
Balance at beginning of period at Mar. 31, 2020		$ 4			$ 3						25,866	(74,809)	(5,139)	(46,351)		(100,426)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020		43,354,000			30,564,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class B Common Stock for Class A Common Stock											(1,580)			1,580
Exchange of Class B Common Stock for Class A Common Stock (in shares)		2,055,000			(2,055,000)
Exchange of Class A Common Stock for Series B-1 Preferred Stock		$ (2)							$ 1		1
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)		(15,810,000)							158,000
Distributions to noncontrolling interest														(800)		(800)
Exercise of warrants		$ 1									17,627					17,628
Exercise of warrants (in shares)		1,034,000
Equity-based compensation											3,244					3,244
Equity-based compensation (in shares)		32,000
Net income (loss)												4,470		3,388		7,858
Equity activity resulting from Tax Receivable Agreement											2,223					2,223
Equity activity resulting from the Put/Call Agreement											(29,927)					(29,927)
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													(656)	(410)		(1,066)
Balance at end of period at Jun. 30, 2020		$ 3			$ 3				$ 1		17,454	(70,339)	(5,795)	(42,593)		(101,266)
Shares, Outstanding, Ending Balance at Jun. 30, 2020		30,665,000			28,509,000				158,000
Balance at beginning of period at Dec. 31, 2020		$ 8			$ 1				$ 1		558,486	(199,196)	(4,411)	(74,044)		280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020		76,458,000			13,219,000				164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions		$ 2	$ 564,986	$ 564,988			$ 523,856	$ 523,856
Issuance of stock for acquisitions (in shares)		14,092,000				130,000
Issuance of stock options for acquisition											134,683					134,683
Sale of stock, net of offering costs	$ 1									$ 265,017					$ 265,018
Sale of stock (in shares)	8,450,000
Exchange of Class B Common Stock for Class A Common Stock		$ 1			$ (1)						(77,919)			77,919
Exchange of Class B Common Stock for Class A Common Stock (in shares)		13,219,000			(13,219,000)
Cashless exercise of options (in shares)		9,000
Equity-based compensation											8,582					8,582
Equity-based compensation (in shares)		172,000
Conversion of Series B-1 Preferred Stock to Class A Common Stock (in shares)		3,950,000							(40,000)
Conversion of Series C-1 Preferred Stock to Class A Common Stock		$ (1)									1
Conversion Of Series C-1 Preferred Stock to Class A Common Stock (in shares)		13,047,000							(130,000)
Class A Common Stock issued in connection with Employee Stock Purchase Plan											314					314
Class A Common Stock issued in connection with Employee Stock Purchase Plan (in shares)		8,000
Net income (loss)												(3,966)		324		(3,642)
Equity activity resulting from Tax Receivable Agreement											16,768					16,768
Other											(810)					(810)
Other (in shares)		(19,000)
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													1,876			1,876
Balance at end of period at Mar. 31, 2021		$ 13							$ 1		1,993,962	(203,162)	(2,535)	4,199		1,792,478
Shares, Outstanding, Ending Balance at Mar. 31, 2021		129,386,000							124,000
Balance at beginning of period at Dec. 31, 2020		$ 8			$ 1				$ 1		558,486	(199,196)	(4,411)	(74,044)		280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020		76,458,000			13,219,000				164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class B Common Stock for Class A Common Stock																$ 77,900
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)				3,950,000
Exercise of stock options (in shares)																216,000
Net income (loss)																$ 76,416
Balance at end of period at Jun. 30, 2021		$ 13							$ 1		2,015,875	(124,055)	(1,871)	4,080		1,894,043
Shares, Outstanding, Ending Balance at Jun. 30, 2021		130,064,000							124,000
Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Distributions to noncontrolling interest														(1,070)		(1,070)
Balance at beginning of period at Mar. 31, 2021		$ 13							$ 1		1,993,962	(203,162)	(2,535)	4,199		1,792,478
Shares, Outstanding, Beginning Balance at Mar. 31, 2021		129,386,000							124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions											12,166					12,166
Issuance of stock for acquisitions (in shares)		441,000
Exercise of stock options											2,300					$ 2,300
Exercise of stock options (in shares)		200,000														200,000
Distributions to noncontrolling interest														(1,070)		$ (1,070)
Equity-based compensation											7,447					7,447
Equity-based compensation (in shares)		37,000
Net income (loss)												79,107		951		80,058
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													664			664
Balance at end of period at Jun. 30, 2021		$ 13							$ 1		$ 2,015,875	$ (124,055)	$ (1,871)	$ 4,080		$ 1,894,043
Shares, Outstanding, Ending Balance at Jun. 30, 2021		130,064,000							124,000

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	Jan. 08, 2021	Mar. 31, 2021	Jun. 30, 2021
Offering costs			$ 13,832
Public Offering [Member]
Offering costs	$ 13,800	$ 13,832

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income (loss)	$ 76,416	$ (41,595)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	86,768	35,114
Equity-based compensation	16,029	5,467
Change in fair value of contingent consideration - common shares liability	(24,044)	16,325
Change in fair value of warrant liability	(40,622)	35,446
Deferred income tax expense (income)	6,544	(1,613)
Change in fair value of interest rate swaps, net of reclassification adjustment	(1,443)	(1,415)
Change in fair value of contingent consideration	255	(2,900)
Payment of contingent consideration in connection with acquisition - operating		(1,000)
Amortization of intangible assets	24,231	0
Amortization of deferred financing costs	2,306	783
Imputed interest expense	173
Write-off of deferred financing costs	3,495
Loss on extinguishment of debt from prepayment penalty	8,454
Gain on sale of investment		(591)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(4,608)	(20,506)
Inventory	15,841	(6,792)
Prepaid and other assets	8,678	3,603
Accounts payable and accrued expenses and other current liabilities	(30,849)	90,682
Net cash provided by operating activities	147,624	111,008
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired	(1,292,631)	(107,463)
Purchases of equipment and other fixed assets	(79,396)	(10,915)
Payments for investments in cost-method companies		(1,000)
Proceeds from sale of investment		2,046
Net cash used in investing activities	(1,372,027)	(117,332)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	1,070,000	70,000
Repayments on long-term debt and lines of credit	(470,521)	(21,641)
Proceed from issuance/sale of Class A Common Stock	278,850
Proceeds from the issuance of senior unsecured notes	500,000
Proceeds from exercise of warrants		11,883
Proceeds from exercise of stock options	2,300
Payments on capital leases	(19,767)	(19,409)
Payments for equity issuance costs	(13,832)
Payments of deferred financing costs	(18,039)
Proceeds received in connection with employee stock purchase plan	314
Payments for tax withholdings from equity-based compensation activity, net	(810)
Distributions to noncontrolling interest	(1,070)	(800)
Payment of contingent consideration in connection with acquisition- financing	(13,396)
Payment of deferred purchase price in connection with an acquisition	(2,945)
Payments for debt prepayment penalties	(8,454)
Net cash provided by financing activities	1,302,630	40,033
Net increase in cash and cash equivalents	78,227	33,709
Cash and cash equivalents - beginning of the period	99,962	76,878
Cash and cash equivalents - end of the period	178,189	110,587
Supplemental disclosures:
Cash paid for interest	30,382	15,488
Cash paid for income taxes	13,756	2,155
Noncash investing and financing activities:
Equipment acquired under capital lease obligations	18,644	20,632
Unpaid equipment and other fixed asset purchases at end of year	20,114	6,990
Equity consideration issued in connection with acquisitions	1,235,693	6,248
Contingent purchase price in connection with acquisitions	1,000
Deferred purchase price in connection with acquisitions	$ 983	$ 33

General Information

General Information	6 Months Ended
	Jun. 30, 2021
General Information
General Information	(1) General Information AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), f/k/a DFB Healthcare Acquisitions Corp. (DFB), is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. AdaptHealth focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM) and insulin pumps), (iii) home medical equipment (HME) to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME medical devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial payors. ​ On July 8, 2019, AdaptHealth Holdings LLC (AdaptHealth Holdings) entered into an Agreement and Plan of Merger (the Merger Agreement), as amended on October 15, 2019, with DFB, pursuant to which AdaptHealth Holdings combined with DFB (the Business Combination). The Business Combination closed on November 8, 2019. ​ Unless the context otherwise requires, “the Company”, “we,” “us,” and “our” refer, for periods prior to the closing of the Business Combination, to AdaptHealth Holdings and its subsidiaries and, for periods upon or after the closing of the Business Combination, to AdaptHealth Corp. and its subsidiaries, including AdaptHealth Holdings and its subsidiaries. ​ The consolidated interim financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020. Interim results are not necessarily indicative of the results for a full year. ​ There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020. ​ (a) Basis of Presentation The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure has been restated to that of the Company. As of June 30, 2021, the Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more during such fiscal year, (iii) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock in the IPO, which would be December 31, 2023. The Company will no longer qualify as an emerging growth company as of December 31, 2021 due to the market value of its Common Stock that was held by non-affiliates as of June 30, 2021. (b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. (c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. (d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates. (e) Valuation of Goodwill The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. (f) Impairment of Long Lived Assets The Company’s long lived assets, such as equipment and other fixed assets and definite-lived identifiable intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the identifiable intangible assets acquired: ​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years ​ The Company did not incur any impairment charges on long-lived assets for the three and six months ended June 30, 2021 and 2020. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long lived assets. (g) Business Segment The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure. (h) Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which requires lessees to recognize leases on its-balance sheet and disclose key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on the balance sheet for most leases. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The Company expects to elect the “package of practical expedients” under the new standard, which, among other things, permits lease agreements that are twelve months or less to be excluded from the balance sheet, and permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company will adopt the new standard during the year ended December 31, 2021. The Company expects to adopt this guidance using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application, and will recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company expects that this standard will have a material effect on its consolidated financial statements. While the Company continues to assess all of the effects of the adoption, it currently estimates that upon adoption it will record approximately $88 million to $98 million of operating lease liabilities on its consolidated balance sheet, with a corresponding ROU asset, based on the present value of the remaining minimum rental payments under the current leasing standard for existing operating leases. This amount is estimated as of the date of initial application ( January 1, 2021 ), and will be impacted by changes to the existing operating leases during 2021 for new leases, lease amendments, lease terminations and acquisitions. The Company does not expect the adoption will have an impact on its accounting for existing capital leases. The adoption will also require significant new disclosures about the Company’s leasing activities. Additionally, the Company estimates that it will record approximately $55 million to $65 million of operating lease liabilities on its consolidated balance sheet, with a corresponding ROU asset , based on the present value of the remaining minimum rental payments under the current leasing standard for operating leases acquired by the Company in connection with the acquisition of AeroCare Holdings, Inc. (AeroCare) on February 1, 2021 (note 3). The Company is implementing a lease management system to track and record the lease liabilities and ROU asset for all leases with a term of greater than 12 months. The Company is also in the process of completing additional process changes and updating internal controls to ensure the new reporting and disclosure requirements are met upon adoption. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ​ In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) ​ (i) Reclassifications ​ Certain prior year amounts have been reclassified to conform to the current year presentation. ​

Revenue Recognition and Account

Revenue Recognition and Accounts Receivable	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Accounts Receivable	(2) Revenue Recognition and Accounts Receivable Revenue Recognition The Company generates revenues for services and related products that the Company provides to patients for home medical equipment, related supplies, and other items. The Company’s revenues are recognized in the period in which services and related products are provided to customers and are recorded either at a point in time for the sale of supplies and disposables, or over the fixed monthly service period for equipment. Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to receive from patients or under reimbursement arrangements with Medicare, Medicaid and third-party payors, in exchange for those goods and services. The Company determines the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration, such as implicit price concessions. The Company utilizes the expected value method to determine the amount of variable consideration that should be included to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The Company applies constraint to the transaction price, such that net revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such adjustments become known. Sales revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenues for the sale of durable medical equipment and related supplies, including oxygen equipment, ventilators, wheelchairs, hospital beds and infusion pumps, are recognized when control of the promised good or service is transferred to customers, which is generally upon shipment for direct to consumer supplies and upon delivery to the home for durable medical equipment. ​ The Company provides certain equipment to patients which is reimbursed periodically in fixed monthly payments for as long as the patient is using the equipment and medical necessity continues (in certain cases, the fixed monthly payments are capped at a certain amount). The equipment provided to the patient is based upon medical necessity as documented by prescriptions and other documentation received from the patient’s physician. The patient generally does not negotiate or have input with respect to the manufacturer or model of the equipment prescribed by their physician and delivered by the Company. Once initial delivery of this equipment is made to the patient for initial setup, a monthly billing process is established based on the initial setup service date. The Company recognizes the fixed monthly revenue ratably over the service period as earned, less estimated adjustments, and defers revenue for the portion of the monthly bill that is unearned. No separate revenue is earned from the initial setup process. Included in fixed monthly revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of net unbilled fixed monthly revenue recognized is based on historical trends and estimates of future collectability. ​ The Company’s billing system contains payor-specific price tables that reflect the fee schedule amounts in effect or contractually agreed upon by various government and commercial payors for each item of equipment or supply provided to a customer. Revenues are recorded based on the applicable fee schedule. The Company has established a contractual allowance to account for adjustments that result from differences between the payment amount received and the expected realizable amount. If the payment amount received differs from the net realizable amount, an adjustment is recorded to revenues in the period that these payment differences are determined. The Company reports revenues in its consolidated financial statements net of such adjustments. ​ The Company’s business experiences some seasonality. Its patients are generally responsible for a greater percentage of the cost of their treatment or therapy during the early months of the calendar year due to co-insurance, co-payments and deductibles, and therefore may defer treatment and services of certain therapies until meeting their annual deductibles. In addition, changes to employer insurance coverage often go into effect at the beginning of each calendar year which may impact eligibility requirements and delay or defer treatment. These factors may lead to lower net revenue and cash flow in the early part of the year versus the latter half of the year. Additionally, the increased incidence of respiratory infections during the winter season may result in initiation of additional respiratory services such as oxygen therapy for certain patient populations. The Company’s net revenue and quarterly operating results may fluctuate significantly in the future depending on these and other factors. ​ The Company recognizes revenue in the consolidated statements of operations and contract assets on the consolidated balance sheets only when services have been provided. Since the Company has performed its obligation under the contract, it has unconditional rights to the consideration recorded as contract assets and therefore classifies those billed and unbilled contract assets as accounts receivable. ​ Fixed monthly payments that the Company receives from customers in advance of providing services represent contract liabilities. Such payments primarily relate to patients who are billed monthly in advance and are recognized over the period as earned. ​ The Company disaggregates net revenue from contracts with customers by payor type and by core service lines. The Company believes that disaggregation of net revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The payment terms and conditions within the Company’s revenue-generating contracts vary by payor type and payor source. The composition of net revenue by payor type for the three and six months ended June 30, 2021 and 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Insurance ​ $ 371,869 ​ $ 148,165 ​ $ 661,879 ​ $ 262,616 Government ​ ​ 177,323 ​ ​ 60,513 ​ ​ 311,053 ​ ​ 111,758 Patient pay ​ 67,825 ​ 23,438 ​ 126,204 ​ 49,181 Net revenue ​ $ 617,017 ​ $ 232,116 ​ $ 1,099,136 ​ $ 423,555 ​ The composition of net revenue by core service lines for the three and six months ended June 30, 2021 and 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 163,331 ​ $ 84,421 ​ $ 292,013 ​ $ 153,315 Diabetes ​ ​ 123,314 ​ ​ 6,372 ​ ​ 218,331 ​ ​ 11,679 Supplies to the home ​ ​ 42,675 ​ ​ 27,868 ​ ​ 84,038 ​ ​ 55,900 Respiratory ​ 13,154 ​ 18,114 ​ 18,775 ​ 20,882 HME ​ ​ 30,360 ​ ​ 12,727 ​ ​ 54,516 ​ ​ 24,306 Other ​ ​ 27,763 ​ ​ 11,463 ​ ​ 50,189 ​ ​ 23,856 Total net sales revenue ​ $ 400,597 ​ $ 160,965 ​ $ 717,862 ​ $ 289,938 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 66,335 ​ $ 22,644 ​ $ 114,444 ​ $ 45,313 Diabetes ​ ​ 3,216 ​ ​ — ​ ​ 6,069 ​ ​ — Respiratory ​ 111,528 ​ 30,856 ​ 194,982 ​ 55,863 HME ​ ​ 24,431 ​ ​ 13,262 ​ ​ 44,811 ​ ​ 25,439 Other ​ ​ 10,910 ​ ​ 4,389 ​ ​ 20,968 ​ ​ 7,002 Total net revenue from fixed monthly equipment reimbursements ​ $ 216,420 ​ $ 71,151 ​ $ 381,274 ​ $ 133,617 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 229,666 ​ $ 107,065 ​ $ 406,457 ​ $ 198,628 Diabetes ​ ​ 126,530 ​ ​ 6,372 ​ ​ 224,400 ​ ​ 11,679 Supplies to the home ​ ​ 42,675 ​ ​ 27,868 ​ ​ 84,038 ​ ​ 55,900 Respiratory ​ 124,682 ​ 48,970 ​ 213,757 ​ 76,745 HME ​ ​ 54,791 ​ ​ 25,989 ​ ​ 99,327 ​ ​ 49,745 Other ​ ​ 38,673 ​ ​ 15,852 ​ ​ 71,157 ​ ​ 30,858 Total net revenue ​ $ 617,017 ​ $ 232,116 ​ $ 1,099,136 ​ $ 423,555 ​ In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, the Company increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by CMS under the CARES Act legislation, which was received in April 2020. In addition, in connection with an acquisition completed in July 2020, the Company assumed a liability of $3.7 million relating to funds received by the acquired company prior to the date of acquisition for CMS recoupable advance payments. The recoupment of the advance payments by CMS has begun in April 2021 and is being applied to services provided and revenue recognized during the period in which the recoupment occurs, and will impact the Company’s cash receipts for services provided until such time all amounts have been recouped. During the three months ended June 30, 2021, CMS has recouped a total of $15.9 million. At June 30, 2021, the Company has deferred a total of $33.6 million related to CMS recoupable advance payments, which is included in other current liabilities in the consolidated balance sheet as of June 30, 2021. Accounts Receivable Due to the continuing changes in the healthcare industry and third-party reimbursement environment, certain estimates are required to record accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded. The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. Management’s evaluation takes into consideration such factors as historical cash collections experience, business and economic conditions, trends in healthcare coverage, other collection indicators and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their estimated net realizable value. Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to net revenue in the period of revision. Included in accounts receivable are earned but unbilled accounts receivables. Billing delays, ranging from several days to several weeks, can occur due to the Company’s policy of compiling required payor specific documentation prior to billing for its services rendered. At June 30, 2021 and December 31, 2020, the Company recorded unbilled accounts receivables of $18.3 million and $20.2 million, respectively.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Acquisitions	(3) Acquisitions During the six months ended June 30, 2021 and 2020, the Company completed several acquisitions to strengthen its current market share in existing markets or to expand into new markets. Each of the Company’s acquisitions was accounted for using the acquisition method pursuant to the requirements of FASB ASC Topic 805, Business Combinations Six Months Ended June 30, 2021 On February 1, 2021, the Company acquired 100% of the equity interests of AeroCare Holdings, Inc. (AeroCare). AeroCare is a leading national technology-enabled respiratory and home medical equipment distribution platform in the United States and offers a comprehensive suite of direct-to-patient equipment and services including CPAP and BiPAP machines, oxygen concentrators, home ventilators, and other durable medical equipment products. The total consideration consisted of (i) a cash payment of approximately $1.1 billion at closing, (ii) the issuance of 13,992,615 shares of the Company’s Class A Common Stock at closing, (iii) the issuance of 130,474.73 shares of the Company’s Series C Convertible Preferred Stock at closing, and (iv) the issuance of 3,959,892 options to purchase shares of the Company’s Class A Common Stock in the future, which had a weighted-average exercise price of $6.24 per share and a weighted-average remaining exercise period of approximately 7 years from the date of closing. Refer to Note 10, Stockholders’ Equity – Preferred Stock $20.9 million of net liabilities to other working capital accounts. In July 2021, the Company paid $4.1 million to the AeroCare sellers in connection with a post-closing net working capital adjustment, which was recorded as additional goodwill in July 2021. On April 30, 2021, the Company acquired 100% of the equity interests of Spiro Health Services, LLC (Spiro). Spiro is a provider of home medical equipment and supplies. The total consideration consisted of a cash payment of $66.1 million at closing, the issuance of 244,641 shares of the Company’s Class A Common Stock at closing, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s preliminary acquisition accounting. Such amount is included in other current liabilities in the accompanying consolidated balance sheets at June 30, 2021 based on the expected payment date. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $2.1 million to cash, $7.3 million to accounts receivable, $4.9 million to inventory, $2.2 million to equipment and other fixed assets, $1.0 million to identifiable intangible assets (consisting of tradenames), $63.8 million to goodwill, $5.1 million to accounts payable and accrued expenses, $2.2 million to capital lease obligations, and $0.2 million of net assets to other working capital accounts. On June 1, 2021, the Company acquired 100% of the equity interests of Healthy Living Medical Supply, LLC (Healthy Living). Healthy Living is a provider of continuous glucose monitors and insulin pumps. The total consideration consisted of a cash payment of $47.0 million at closing and the issuance of 196,779 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.6 million to cash, $7.5 million to accounts receivable, $2.9 million to inventory, $1.5 million to equipment and other fixed assets, $1.3 million to identifiable intangible assets (consisting of tradenames), $41.7 million to goodwill, $3.6 million to accounts payable and accrued expenses, and $0.2 million of net assets to other working capital accounts. In addition, during the six months ended June 30, 2021, the Company acquired 100% of the equity interests of two providers of home medical equipment and acquired certain assets of the durable medical equipment business of a provider of home medical equipment. The total consideration paid for these three acquisitions consisted of cash payments of $57.5 million at closing, a $0.9 million cash payment during the six months ended June 30, 2021 for a post-closing net working capital adjustment, and the issuance of 99,695 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid for these three acquisitions to the estimated fair values of the net assets acquired on a provisional basis, including $1.5 million to cash, $6.4 million to accounts receivable, $3.8 million to inventory, $12.0 million to equipment and other fixed assets, $1.5 million to identifiable intangible assets (consisting of tradenames), $41.2 million to goodwill, $4.7 million to accounts payable and accrued expenses, and $0.2 million of net liabilities to other working capital accounts. One of the acquisitions also includes potential contingent payments of up to $4.0 million based on certain conditions after closing, which was determined to have a nominal acquisition date fair value, and thus no contingent consideration liability was recorded in connection with the Company’s preliminary acquisition accounting for the acquisition. In addition, during the six months ended June 30, 2021, the Company completed certain other acquisitions. In the aggregate the consideration paid consisted of cash payments of $4.9 million at closing and deferred payment liabilities of $1.0 million. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.4 million to accounts receivable, $0.2 million to inventory, $0.7 million to equipment and other fixed assets, $4.9 million to goodwill, $0.2 million to accounts payable and accrued expenses, and $0.1 million of net liabilities to other working capital accounts. The following table summarizes the consideration paid for all acquisitions during the six months ended June 30, 2021 (in thousands): ​ ​ ​ ​ ​ Cash consideration ​ $ 1,325,133 Equity consideration ​ 1,235,693 Contingent consideration ​ ​ 1,000 Deferred payments ​ 983 Total ​ $ 2,562,809 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. The Company is still evaluating the fair value of certain assets and liabilities for which provisional amounts were recorded and expects to finalize such valuations during the remainder of 2021. Based upon management’s evaluation, which is preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the six months ended June 30, 2021 was allocated as follows during such period (in thousands): ​ ​ ​ ​ ​ Cash ​ $ 31,944 Accounts receivable ​ 97,523 Inventory ​ 39,525 Prepaid and other current assets ​ 4,828 Equipment and other fixed assets ​ 179,761 Goodwill ​ 2,254,990 Identifiable intangible assets ​ ​ 142,000 Other assets ​ ​ 1,194 Deferred tax liabilities ​ ​ (63,222) Accounts payable and accrued expenses ​ (96,325) Contract liabilities ​ ​ (14,583) Other current liabilities ​ ​ (11,576) Other long-term liabilities ​ ​ (1,055) Capital lease obligations ​ (2,195) Net assets acquired ​ $ 2,562,809 ​ During the six months ended June 30, 2021, the Company received net cash receipts of $0.6 million relating to working capital adjustments associated with businesses that were acquired during 2020 which was recorded as a decrease to goodwill during the period. ​ Six Months Ended June 30, 2020 ​ On January 2, 2020, the Company purchased 100% of the equity interests of the Patient Care Solutions business (PCS), which was a subsidiary of McKesson Corporation. PCS is a home medical equipment supplies business. The total consideration consisted of a cash payment of $15.0 million. During the six months ended June 30, 2020, the Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $16.3 million to accounts receivable, $0.5 million to equipment and other fixed assets, $1.4 million to goodwill, and $3.2 million of net liabilities to other working capital accounts. ​ On March 2, 2020, the Company purchased certain assets of the durable medical equipment business of Advanced Home Care, Inc. (Advanced). The total consideration consisted of a cash payment of $58.5 million at closing. During the six months ended June 30, 2020, the Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $18.4 million to equipment and other fixed assets, $39.6 million to goodwill, and $0.5 million of net assets to other working capital accounts. The acquisition of Advanced also includes a potential contingent payment of up to $9.0 million based on certain conditions after closing. As of June 30, 2020, the Company had not yet determined the fair value of such contingent payment, as such an estimated fair value was not included in the consideration paid as part of the Company’s preliminary acquisition accounting during the six months ended June 30, 2020. Subsequent to June 30, 2020, the Company determined that the potential contingent payment had an acquisition date fair value of $5.0 million which was recorded as a contingent liability. The fair value of the estimated contingent liability of $5.0 million at June 30, 2021 is included in other current liabilities in the accompanying consolidated balance sheets based on the expected payment date. ​ In addition, during the six months ended June 30, 2020, the Company acquired 100% of the equity interests of a provider of home medical equipment. The total consideration consisted of a cash payment of $32.4 million at closing and the issuance of 386,874 shares of the Company’s Class A Common Stock at closing. The Company allocated the consideration paid for this acquisition to the estimated fair values of the net assets acquired on a provisional basis, including $0.3 million to cash, $3.3 million to accounts receivable, $1.4 million to inventory, $5.9 million to equipment and other fixed assets, $33.7 million to goodwill, $2.9 million to accounts payable and accrued expenses, $1.6 million to capital lease obligations, and $1.4 million of net liabilities to other working capital accounts. ​ In addition, during the six months ended June 30, 2020, the Company completed certain other acquisitions. In the aggregate the consideration paid consisted of cash payments of $2.2 million at closing and deferred payment liabilities of less than $0.1 million. The Company allocated the consideration paid to the estimated fair values of the net assets acquired on a provisional basis, including $0.4 million to cash, $0.5 million to accounts receivable, $0.3 million to inventory, $0.4 million to equipment and other fixed assets, $1.4 million to goodwill, $0.7 million to accounts payable and accrued expenses, and $0.1 million of net liabilities to other working capital accounts. ​ The following table summarizes the consideration paid for all acquisitions during the six months ended June 30, 2020 (in thousands): ​ ​ ​ ​ ​ Cash consideration ​ $ 108,199 Equity consideration ​ 6,248 Deferred payments ​ ​ 33 Total ​ $ 114,480 ​ The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. Based upon management’s evaluation, which was preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the six months ended June 30, 2020 was allocated as follows during such period (in thousands): ​ ​ ​ ​ ​ Cash ​ $ 736 Accounts receivable ​ 20,118 Inventory ​ 4,413 Prepaid and other current assets ​ 1,334 Equipment and other fixed assets ​ 25,264 Goodwill ​ 76,060 Accounts payable and accrued expenses ​ (6,493) Contract liabilities ​ ​ (3,906) Other liabilities ​ ​ (1,419) Capital lease obligations ​ ​ (1,627) Net assets acquired ​ $ 114,480 ​ The Company finalized the valuations of the fair values of the net assets acquired for these acquisitions during the remainder of 2020. Pro-Forma Information The unaudited pro-forma financial information presented below has been prepared by adjusting the historical results of the Company to include the historical results of the acquisitions described above. The unaudited pro-forma financial information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro-forma information. The unaudited pro-forma financial information does not reflect the impact of future events that may occur after the acquisitions, such as the impact of cost savings or other synergies that may result from these acquisitions, and does not include interest expense associated with debt incurred to fund the acquisitions. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 631,568 ​ $ 572,298 ​ $ 1,224,287 ​ $ 1,102,997 Operating income ​ $ 66,964 ​ $ 55,719 ​ $ 92,600 ​ $ 96,957 ​ Results of Businesses Acquired The following table presents the amount of net revenue and operating income (loss) in the period of acquisition since the respective acquisition dates for the acquisitions described above that is included in the Company’s consolidated statements of operations for the three and six months ended June 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 248,209 ​ $ 53,002 ​ $ 390,856 ​ $ 93,727 Operating income (loss) ​ $ 37,306 ​ $ (2,061) ​ $ 57,689 ​ $ (7,621) ​

Equipment and Other Fixed Asset

Equipment and Other Fixed Assets	6 Months Ended
	Jun. 30, 2021
Equipment and Other Fixed Assets
Equipment and Other Fixed Assets	(4) Equipment and Other Fixed Assets Equipment and other fixed assets as of June 30, 2021 and December 31, 2020 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Patient medical equipment ​ $ 379,683 $ 158,108 Delivery vehicles ​ 21,666 8,211 Other ​ 42,409 26,098 ​ ​ 443,758 ​ 192,417 Less accumulated depreciation ​ (134,687) ​ (81,949) ​ ​ $ 309,071 ​ $ 110,468 ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Identifiable Intangible Assets	(5) Goodwill and Identifiable Intangible Assets Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The change in the carrying amount of goodwill for the six months ended June 30, 2021 was as follows (in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 998,810 Goodwill from acquisitions ​ ​ 2,254,990 Net cash receipts relating to prior acquisitions ​ ​ (558) Reduction ​ ​ (22,042) Balance at June 30, 2021 ​ $ 3,231,200 ​ Annually, and upon the identification of a triggering event, management is required to perform an evaluation of the recoverability of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income or cash flows, and declines in the Company’s stock price or market capitalization. While management cannot predict if or when future goodwill impairments may occur, a goodwill impairment could have a material adverse effect on the Company’s operating income, net assets and the Company’s cost of, or access to, capital. The Company did not record any goodwill impairment charges during the three and six months ended June 30, 2021 and 2020. ​ As discussed in Note 3, Acquisitions ​ Identifiable intangible assets that are separable and have determinable useful lives are valued separately and amortized over the period which reflects the pattern in which the economic benefits of the assets are expected to be consumed. Identifiable intangible assets consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $6,711 ​ $ 98,889 ​ 9.2 Payor contracts, net of accumulated amortization of $7,716 ​ ​ 74,284 ​ 9.1 Contractual rental agreements, net of accumulated amortization of $14,583 ​ ​ 55,417 ​ 1.8 Developed technology, net of accumulated amortization of $1,260 ​ ​ 5,040 ​ 4.0 Identifiable intangible assets, net ​ $ 233,630 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $1,793 ​ $ 32,007 ​ 8.8 Payor contracts, net of accumulated amortization of $3,616 ​ ​ 78,384 ​ 9.6 Developed technology, net of accumulated amortization of $630 ​ ​ 5,670 ​ 4.5 Identifiable intangible assets, net ​ $ 116,061 ​ ​ ​ Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $13.9 million and $24.2 million for the three and six months ended June 30, 2021, respectively. There was no amortization expense related to identifiable intangible assets for the three and six months ended June 30, 2020. ​ Future amortization expense related to identifiable intangible assets is estimated to be as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 55,876 2023 ​ 41,293 2024 ​ 20,876 2025 ​ 20,817 2026 ​ 18,720 Thereafter ​ 76,048 Total ​ $ 233,630 ​ The Company recorded no impairment charges related to identifiable intangible assets during the three and six months ended June 30, 2021 and 2020.

Fair Value of Assets and Liabil

Fair Value of Assets and Liabilities	6 Months Ended
	Jun. 30, 2021
Fair Value of Assets and Liabilities
Fair Value of Assets and Liabilities	(6) Fair Value of Assets and Liabilities FASB ASC Topic 820, Fair Value Measurements and Disclosures ​ ​ ​ Level input ​ Input Definition Level 1 ​ Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level 2 ​ Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Level 3 ​ Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. ​ The following table presents the valuation of the Company’s financial assets and liabilities as of June 30, 2021 and December 31, 2020 measured at fair value on a recurring basis. The fair value estimates presented herein are based on information available to management as of June 30, 2021 and December 31, 2020. These estimates are not necessarily indicative of the amounts the Company could ultimately realize. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 58 ​ $ — ​ $ — Total assets measured at fair value ​ $ 58 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 20,004 Acquisition-related contingent consideration-long term ​ — ​ — ​ 1,568 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,938 ​ ​ — Interest rate swap agreements-long term ​ — ​ 6,240 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 25,758 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 20,675 Warrant liability ​ ​ — ​ ​ — ​ ​ 73,283 Total liabilities measured at fair value ​ $ — ​ $ 12,178 ​ $ 141,288 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 5,602 ​ $ — ​ $ — Total assets measured at fair value ​ $ 5,602 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 23,941 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,599 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,941 ​ ​ — Interest rate swap agreements-long term ​ — ​ 10,220 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 36,846 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 33,631 Warrant liability ​ ​ — ​ ​ — ​ ​ 113,905 Total liabilities measured at fair value ​ $ — ​ $ 16,161 ​ $ 217,922 ​ Interest Rate Swaps The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying consolidated balance sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The Company’s interest rate swaps held as of June 30, 2021 and December 31, 2020 were classified as Level 2 of the fair value hierarchy. Refer to Note 7, Derivative Instruments and Hedging Activities Contingent Consideration The Company estimates the fair value of acquisition-related contingent consideration liabilities by applying the income approach using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Each period, the Company evaluates the fair value of acquisition-related contingent consideration obligations and records any changes in the fair value of such liabilities in other income in the Company’s consolidated statements of operations. At June 30, 2021, contingent consideration liabilities of $20.0 million and $1.6 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. At December 31, 2020, contingent consideration liabilities of $23.9 million and $9.6 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. A reconciliation of the Company’s contingent consideration liabilities related to acquisitions for the six months ended June 30, 2021 and 2020 is as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 33,540 ​ $ 1,000 ​ $ (13,396) ​ $ 255 ​ $ 173 ​ $ 21,572 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ — ​ $ (1,000) ​ $ (2,900) $ — ​ $ 10,825 ​ Contingent Consideration Common Shares Liability ​ The Company estimates the fair value of the contingent consideration common shares liability using a Monte-Carlo simulation analysis. A Monte-Carlo simulation is a tool used to project asset prices based on a widely accepted drift calculation, the volatility of the asset, incremental time-steps and a random component known as a Weiner process that introduces the dynamic behavior in the asset price. In this framework, asset prices follow a log-normal distribution as they fluctuate through time, which the simulation process captures. A specific model can be developed around the projected stock price to capture the effects of any market performance conditions on value. Price path specific conditions can be captured in this type of open form model. The Monte-Carlo process expresses potential future scenarios that when simulated thousands of times can be viewed statistically to ascertain fair value. The contingent consideration common shares contain market conditions to determine whether the shares are earned based on the Company’s common stock price during specified measurement periods. Given the path-dependent nature of the requirement in which the shares are earned, a Monte-Carlo simulation was used to estimate the fair value of the liability. The Company’s common stock price was simulated to each measurement period based on the above described methodology. In each iteration, the simulated stock price was compared to the conditions under which the shares are earned. In iterations where the stock price corresponded to shares being earned, the future value of the earned shares was discounted back to present value. The fair value of the liability was estimated based on the average of all iterations of the simulation. Refer to Note 10, Stockholders’ Equity ​ Warrant Liability ​ The warrant liability represents the estimated fair value of the Company’s outstanding private warrants. The fair value of the private warrants was estimated using the Black-Scholes option pricing model. As an input to the Black-Scholes option pricing model, the volatility implied by trades in the public warrants was considered. In order to estimate this implied volatility, a Monte-Carlo simulation was employed. Refer to the discussion above for a description of the Monte-Carlo simulation analysis. Refer to Note 10, Stockholders’ Equity ​ Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis ​ The following table presents the Company’s hierarchy for non-financial assets measured at fair value on a non-recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 3,231,200 ​ $ 998,810 Identifiable intangible assets, net (Level 3) ​ $ 233,630 ​ $ 116,061 ​ The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). The Company estimates the fair value using the income approach (which is a discounted cash flow technique) or the cost approach. These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential. ​ Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows. ​ The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities	(7) Derivative Instruments and Hedging Activities The Company records all derivatives on its consolidated balance sheet at fair value. As of June 30, 2021 and December 31, 2020, the Company had outstanding interest rate derivatives with third parties in which the Company pays a fixed interest rate and receives a rate equal to the one-month LIBOR. The notional amount associated with the swap agreements was $250 million as of June 30, 2021 and December 31, 2020 and have maturity dates at certain dates through March 2024. The Company has designated its swaps as effective cash flow hedges of interest rate risk. Accordingly, changes in the fair value of the interest rate swaps are recorded as a component of accumulated other comprehensive income (loss) within stockholders’ equity and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. The table below presents the fair value of the Company’s derivatives designated as hedging instruments as well as their classification in the consolidated balance sheets at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,938) ​ $ (5,941) Interest rate swap agreements ​ Other long-term liabilities ​ (6,240) ​ (10,220) Total ​ ​ ​ $ (12,178) ​ $ (16,161) ​ During the three months ended June 30, 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $1.4 million in other comprehensive income (loss). In addition, during the three months ended June 30, 2021, $0.7 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the six months ended June 30, 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $4.0 million in other comprehensive income (loss). In addition, during the six months ended June 30, 2021, $1.4 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the three months ended June 30, 2020, as a result of the effect of cash flow hedge accounting, the Company recognized a loss of $0.4 million in other comprehensive income (loss). In addition, during the three months ended June 30, 2020, $0.7 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the six months ended June 30, 2020, as a result of the effect of cash flow hedge accounting, the Company recognized a loss of $11.1 million in other comprehensive income (loss). In addition, during the six months ended June 30, 2020, $1.4 million was reclassified from other comprehensive income (loss) and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	(8) Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of June 30, 2021 and December 31, 2020 consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 ​ 2020 Accounts payable ​ $ 260,580 $ 191,038 Employee-related accruals ​ 42,854 ​ 26,705 Accrued interest ​ 24,974 ​ 11,062 Other ​ 22,306 ​ 25,407 Total ​ $ 350,714 ​ $ 254,212 ​

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt
Debt	(9) Debt The following is a summary of long term-debt as of June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 ​ 2020 Secured term loans ​ $ 800,000 $ 248,438 Revolving credit facility ​ ​ 175,000 ​ ​ 55,000 Senior unsecured notes ​ ​ 850,000 ​ ​ 350,000 Note payable ​ 71,750 ​ 143,500 Other ​ — ​ 333 Unamortized deferred financing fees ​ (23,674) ​ (12,557) ​ ​ 1,873,076 ​ 784,714 Current portion ​ (96,750) ​ (8,146) Long-term portion ​ $ 1,776,326 ​ $ 776,568 ​ ​ On January 20, 2021, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with its existing bank group, which was subsequently amended in April 2021 (the 2021 Credit Agreement). The 2021 Credit Agreement included borrowings of $800 million under a term loan (the 2021 Term Loan), and $450 million in commitments for revolving credit loans (the 2021 Revolver). The 2021 Revolver has a $55 million letter of credit sublimit. The 2021 Term Loan and the 2021 Revolver both have maturities in January 2026. Borrowings under the 2021 Term Loan were used in part to partially finance the cash portion of the purchase price for the acquisition of AeroCare, to repay existing amounts outstanding under revolving credit loans under the 2021 Credit Agreement which were borrowed prior to the April 2021 amendment, and to repay existing amounts outstanding under the 2020 Credit Agreement (see discussion below), and to pay related fees and expenses. Amounts borrowed under the 2021 Credit Agreement bear interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a floor) equal to the LIBOR (as defined) for the applicable interest period multiplied by the statutory reserve rate, plus (b) an applicable margin (as defined) ranging from 1.50% to 3.25% per annum based on the Consolidated Senior Secured Leverage Ratio (as defined). The 2021 Revolver carries a commitment fee during the term of the 2021 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2021 Revolver based on the Consolidated Senior Secured Leverage Ratio. In connection with the 2021 Credit Agreement, the Company paid financing costs of $7.6 million during the six months ended June 20, 2021. Further, in connection with the transactions completed pursuant to the 2021 Credit Agreement, the Company wrote off unamortized deferred financing costs of $2.1 million, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the six months ended June 30, 2021. During the three months ended March 31, 2021, the Company wrote off $4.2 million of unamortized deferred financing costs in connection with the 2021 Credit Agreement, which was reflected in loss on extinguishment of debt in the Company’s previously issued consolidated statement of operations in such period. During the three months ended June 30, 2021, the Company corrected an error that was identified relating to the accounting for the write off of unamortized deferred financing costs recorded during the three months ended March 31, 2021. As a result of this correction, the Company reversed $2.1 million of the write off that was recorded in the three months ended March 31, 2021, which was reflected as a reduction to the loss on extinguishment of debt recognized during the three months ended June 30, 2021. The impact of such correction was not considered material to the Company’s unaudited consolidated financial statements for the three months ended March 31, 2021 and the three and six months ended June 30, 2021. ​ Under the 2021 Credit Agreement, the Company is subject to a number of restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Interest Coverage Ratio, both as defined in the 2021 Credit Agreement. The 2021 Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder, failure to observe or perform certain covenants, cross-defaults, bankruptcy and insolvency-related events, and non-compliance with healthcare laws. Any borrowing under the 2021 Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid under the 2021 Revolver may be reborrowed. Mandatory prepayments are required under the 2021 Revolver when borrowings and letter of credit usage exceed the total commitments for revolving credit loans. Mandatory prepayments are also required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined, if certain leverage tests are not met. The Company was in compliance with all debt covenants as of June 30, 2021. ​ In July 2020, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with a new bank group (the 2020 Credit Agreement). The 2020 Credit Agreement consisted of a $250 million term loan (the 2020 Term Loan) and $200 million in commitments for revolving credit loans (the 2020 Revolver). The borrowings under the 2020 Term Loan bore interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a floor) equal to the LIBOR (as defined in the 2020 Credit Agreement) for the applicable interest period, plus (b) an applicable margin ranging from 2.50% to 3.75% per annum based on the Consolidated Total Leverage Ratio (as defined in the 2020 Credit Agreement). The 2020 Revolver carried a commitment fee during the term of the 2020 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2020 Revolver based on the Consolidated Total Leverage Ratio. ​ In March 2019, the Company entered into several agreements, amendments and new credit facilities (herein after referred to as the March 2019 Recapitalization Transactions). The March 2019 Recapitalization Transactions included $425 million in new credit facilities, which consisted of a $300 million Initial Term Loan, $50 million Delayed Draw Term Loan, and $75 million Revolving Credit Facility, collectively referred to herein as the 2019 Credit Facility. Amounts borrowed under the 2019 Credit Facility bore interest quarterly at variable rates based upon the sum of (a) the LIBOR Rate for such interest period, plus (b) an applicable margin based upon the Company’s Consolidated Total Leverage Ratio (as defined in the 2019 Credit Facility). In November 2019, the Company repaid $50 million under the Initial Term Loan. In July 2020, the Company amended the 2019 Credit Facility and borrowed $216.3 million; such proceeds were used to partially fund an acquisition. The Company used a portion of the net proceeds from the borrowings under the 2020 Term Loan and the issuance of the 6.125% Senior Notes (see discussion below) to fully repay the outstanding principal balances under the 2019 Credit Facility totaling $523.9 million, and to pay the related accrued interest, fees and expenses. ​ Secured Term Loans ​ The borrowings under the 2021 Term Loan require quarterly principal repayments of $5.0 million beginning June 30, 2021 through March 31, 2023, increasing to $10.0 million beginning June 30, 2023 through December 31, 2025, and the unpaid principal balance is due at maturity in January 2026. At June 30, 2021, there was $800 million outstanding under the 2021 Term Loan. The interest rate under the term loan was 2.13% at June 30, 2021. ​ Revolving Credit Facility ​ During the six months ended June 30, 2021, the Company borrowed $270 million under revolving credit loans pursuant to the 2021 Credit Agreement, of which $175 million was outstanding at June 30, 2021. Borrowings under the 2021 Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the 2021 Credit Agreement. The interest rate under the Company’s revolving credit loans was 2.13% at June 30, 2021. At June 30, 2021, after consideration of stand-by letters of credit outstanding of $14.9 million, the remaining maximum borrowings available pursuant to the Company’s revolving credit loans were $260.1 million. ​ Senior Unsecured Notes ​ On January 4, 2021, the Company issued $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2029 (the 4.625% Senior Notes). The 4.625% Senior Notes will mature on August 1, 2029. Interest on the 4.625% Senior Notes is payable on February 1st and August 1st of each year, beginning on August 1, 2021. The 4.625% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after February 1, 2024, and the redemption price for the 4.625% Senior Notes if redeemed during the 12 months beginning (i) February 1, 2024 is 102.313%, (ii) February 1, 2025 is 101.156%, (iii) February 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 4.625% Senior Notes before February 1, 2024 at a redemption price of 100% of the principal amount of the 4.625% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 4.625% Senior Notes before February 1, 2024 with the proceeds from certain equity offerings at a redemption price equal to 104.625% of the principal amount of the 4.625% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 4.625% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 4.625% Senior Notes were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the issuance of the 4.625% Senior Notes, the Company paid financing costs of $10.4 million. ​ In July 2020, the Company issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the 6.125% Senior Notes). The 6.125% Senior Notes will mature on August 1, 2028. Interest on the 6.125% Senior Notes is payable on February 1st and August 1st of each year, beginning on February 1, 2021. The 6.125 % Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the 6.125 % Senior Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 6.125 % Senior Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the 6.125% Senior Notes , plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 6.125 % Senior Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the 6.125% Senior Notes , together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 6.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. ​ Note Payable ​ In connection with the March 2019 Recapitalization Transactions, the Company signed a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, the Company issued a promissory note with a principal amount of $100 million (the Promissory Note). In connection with the transactions completed as part of the Business Combination, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its members’ interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. In June 2021, the Company agreed with the holders of the New Promissory Note to repay $71.8 million of the outstanding principal amount under the New Promissory Note, and wrote off $1.4 million of unamortized deferred financing costs relating to such principal amount, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations during the three and six months ended June 30, 2021. In addition, in connection with the prepayment of such principal amount, the Company paid a debt prepayment penalty of $8.5 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the June 2021 agreement, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations during the three and six months ended June 30, 2021. Further, the Company has agreed to repay the remaining principal balance of $71.8 million plus accrued interest by September 30, 2021. The Company will also pay a debt prepayment penalty of $7.2 million in connection with that prepayment. The Company expects to repay the remaining outstanding principal by September 30, 2021 using cash on hand and/or borrowings under the 2021 Revolver, and therefore such amount is included in current portion of long-term debt in the accompanying consolidated balance sheets as of June 30, 2021. The outstanding principal balance under the New Promissory Note currently bears interest at 12% and is required to be paid in cash. If the remaining outstanding principal is not repaid by October 31, 2021, the New Promissory Note will be amended to provide that the outstanding principal amount will bear interest at the greater of (i) 15% per annum or (ii) the twelve-month LIBOR plus 12% per annum and will have a maturity date of November 8, 2029. ​ In May 2020, the Company and the investor entered into a Put/Call Option and Consent Agreement (the Put/Call Agreement), pursuant to which certain put and call rights were granted to the parties with respect to shares of Class A Common Stock, shares of Class B Common Stock, and common units of AdaptHealth Holdings (each such common unit, together with one share of Class B Common Stock, a Consideration Unit) held by the investor at the time. Pursuant to the Put/Call Agreement, which was amended in October 2020, during the period from July 1, 2020 to December 31, 2020 (the Option Period), the investor could require the Company to purchase up to 1,898,967 shares of Class A Common Stock and/or Consideration Units held by the investor (such shares of Class A Common Stock and Consideration Units, collectively, Interests) at a price per share of Class A Common Stock or per Consideration Unit equal to the greater of (x) $14.50 and (y) 85% of the 30-day volume-weighted average price per share of the Company’s Class A Common Stock on the date the exercise notice is delivered. During the Option Period, the Company could also require the investor to sell up to 1,898,967 of the Interests held by the investor to the Company at a price per share of Class A Common Stock or per Consideration Unit of $15.76. In addition, under the Put/Call Agreement, the investor waived certain consent rights under the New Promissory Note. In connection with the Put/Call Agreement, during the six months ended June 30, 2020, the Company recorded a decrease to additional paid-in capital of $29.9 million, representing the settlement amount of the related call option, and classified such amount as mezzanine equity at such date.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity
Stockholders' Equity	(10) Stockholders’ Equity On January 8, 2021, the Company issued 8,450,000 shares of Class A Common Stock at a price of $33.00 per share pursuant to an underwritten public offering (the 2021 Stock Offering) for gross proceeds of $278.9 million. In connection with this transaction, the Company received proceeds of $265.6 million which is net of the underwriting discount. A portion of the proceeds from the 2021 Stock Offering were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the 2021 Stock Offering, the Company paid offering costs, inclusive of the underwriting discount, of $13.8 million. Upon the Closing of the Business Combination, the former owners of AdaptHealth Holdings held approximately 49% of the economic interest in AdaptHealth Corp. and the former stockholders of DFB held the remaining approximate 51% of the economic interests in AdaptHealth Corp., both in the form of shares of the Company’s Class A Common Stock. In addition, AdaptHealth Corp. owned approximately 56% of the combined company with the remaining 44% owned by the former owners of AdaptHealth Holdings in the form of common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing of the Business Combination (New AdaptHealth Units). ​ Following the Closing of the Business Combination, the combined results of DFB and AdaptHealth Holdings are consolidated, and the holders of Class A Common Stock owned an approximate 56% direct controlling interest and the holders of New AdaptHealth Units owned an approximate 44% direct noncontrolling economic interest shown as noncontrolling interest in the consolidated financial statements of the combined entity. The direct noncontrolling economic interest in AdaptHealth Holdings held by the owners of AdaptHealth Holdings was in the form of New AdaptHealth Units (and a corresponding number of non-economic shares of Class B Common Stock) and were exchangeable on a one-to-one basis for shares of Class A Common Stock. Following the Closing of the Business Combination, all of the New AdaptHealth Units and a corresponding number of shares of Class B Common Stock were exchanged for shares of Class A Common Stock, of which the final 13,218,758 of the exchanges occurred on January 1, 2021. As a result, there are no New AdaptHealth Units and shares of Class B Common Stock outstanding, and therefore the prior holders of New AdaptHealth Units no longer own a direct noncontrolling economic interest in AdaptHealth Holdings. Accordingly, the Company recorded a decrease to the noncontrolling interest of $77.9 million during the six months ended June 30, 2021 in the accompanying consolidated statements of stockholders’ equity (deficit). ​ Following the filing of the Charter with the Secretary of State of the State of Delaware on July 28, 2021, the Company’s Class A Common Stock was renamed to Common Stock, and the Common Stock is the sole class of common stock of the Company. ​ Preferred Stock In June 2020, the Company entered into an exchange agreement (the Exchange Agreement) with an investor pursuant to which the investor exchanged 15,810,547 shares of the Company’s Class A Common Stock for 158,105.47 shares of Series B-1 Preferred Stock, par value $0.0001 per share. The Series B-1 Preferred Stock liquidation preference is limited to its par value of $0.0001 per share. The Series B-1 Preferred Stock will participate equally and ratably on an as-converted basis with the holders of Common Stock in all cash dividends paid on the Common Stock. The Series B-1 Preferred Stock is non-voting. The holder may convert each share of Series B-1 Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments) at its election, except to the extent that following such conversion, the number of shares of Common Stock held by such holder and its affiliates exceed 4.9% of the outstanding Common Stock of the Company. During the six months ended June 30, 2021, 39,500 shares of Series B-1 Preferred Stock were converted into 3,950,000 shares of Class A Common Stock. As discussed in Note 3, Acquisitions Warrants At the Closing of the Business Combination, the Company had 12,666,666 warrants outstanding. Each warrant is exercisable into one share of Common Stock at a price of $11.50 per share. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for the issuance of common stock at a price below its exercise price. As of March 31, 2021, 8,386,118 warrants were exercised. As of June 30, 2021, the Company had 4,280,548 warrants outstanding, which have an expiration date of November 20, 2024. The estimated fair value of the warrants is recorded as a liability in the Company’s consolidated balance sheet, with such fair value reclassified to stockholders’ equity upon the exercise of such warrants. Prior to exercise, the change in the estimated fair value of such warrants each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations. A reconciliation of the changes in the warrant liability during the six months ended June 30, 2021 and 2020 was as follows (in thousands): ​ ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2020 ​ $ 113,905 Change in estimated fair value of the warrant liability ​ ​ (40,622) Estimated fair value of warrant liability at June 30, 2021 ​ $ 73,283 ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2019 ​ $ 27,635 Change in estimated fair value of the warrant liability ​ ​ 35,446 Reclassification of warrant liability to equity for exercised warrants ​ (21,019) Estimated fair value of warrant liability at June 30, 2020 ​ $ 42,062 ​ Contingent Consideration Common Shares Pursuant to the Merger Agreement, the former owners of AdaptHealth Holdings who received Class A Common Stock and Class B Common Stock in connection with the Business Combination are entitled to receive earn-out consideration to be paid in the form of Class A Common Stock, if the average price of the Company’s Class A Common Stock for the month of December prior to each measurement date equals or exceeds certain hurdles set forth in the Merger Agreement (Contingent Consideration Common Shares). The former owners of AdaptHealth Holdings were entitled to receive 1,000,000 shares of Class A Common Stock on December 31, 2020 based on an average stock price hurdle of $15. The average stock price of the Company’s Class A Common Stock was greater than $15 per share for the applicable measurement period as of the December 31, 2020 measurement date, which triggered the issuance of 1,000,000 shares of Class A Common Stock at such date. In addition, the former owners of AdaptHealth Holdings are entitled to receive up to an additional 1,000,000 shares of Common Stock on each of December 31, 2021 and 2022 (each a measurement date) and such average stock price hurdles are $18 and $22 at each measurement date, respectively. The Contingent Consideration Common Shares would be issued immediately in the event of a change of control as defined in the Merger Agreement. The estimated fair value of the Contingent Consideration Common Shares is recorded as a liability in the Company’s consolidated balance sheet, with such fair value reclassified to stockholders’ equity upon the issuance of any shares that are earned. Prior to issuance, the change in the estimated fair value of such shares each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations. A reconciliation of the changes in the contingent consideration common shares liability during the six months ended June 30, 2021 and 2020 was as follows (in thousands): ​ ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2020 ​ $ 70,477 Change in estimated fair value of the contingent consideration common shares liability ​ ​ (24,044) Estimated fair value of contingent consideration common shares liability at June 30, 2021 ​ $ 46,433 ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2019 ​ $ 9,316 Change in estimated fair value of the contingent consideration common shares liability ​ 16,325 Estimated fair value of contingent consideration common shares liability at June 30, 2020 ​ $ 25,641 ​ The total estimated fair value of the contingent consideration common shares liability at June 30, 2021 is classified as a current liability ( $25.7 balance sheet as of such date based on the estimated issuance dates of such shares. The total estimated fair value of the contingent consideration common shares liability at December 31, 2020 is classified as a current liability ( $36.9 The decrease in the estimated fair value of the contingent consideration common shares liability of $24.0 million during the six months ended June 30, 2021 was recorded as a non-cash gain in the Company’s consolidated statements of operations during such period. The increase in the estimated fair value of the contingent consideration common shares liability of $16.3 million during the six months ended June 30, 2020 was recorded as a non-cash charge in the Company’s consolidated statements of operations during such period. Equity-based Compensation In connection with the Company’s 2019 Stock Incentive Plan (the 2019 Plan), the Company provides equity-based compensation to attract and retain employees while also aligning employees’ interest with the interests of its stockholders. The 2019 Plan permits the grant of various equity-based awards to selected employees and non-employee directors. At June 30, 2021, the 2019 Plan permits the grant of up to 8,000,000 shares of Common Stock, subject to certain adjustments and limitations. At June 30, 2021, 1,573,266 shares of the Company’s Common Stock were available for issuance under the 2019 Plan. On July 27, 2021, at the annual meeting of stockholders of the Company, the stockholders of the Company approved an amendment and restatement of the 2019 Plan to, among other things, increase the number of shares of Common Stock of the Company reserved under the 2019 Plan by 2,000,000 shares, to permit the grant of up to 10,000,000 shares of Common Stock, subject to certain adjustments and limitations. The following awards were granted in connection with the 2019 Plan during the six months ended June 30, 2021. Stock Options In January 2021, the Company granted 703,170 options to purchase shares of the Company’s Class A Common Stock to certain senior executives of the Company. The options vest ratably over a three-year period from the date of grant based on only a service condition and have a contractual exercise period of five years from the date of grant. The total grant-date fair value of the options granted, using a Black-Scholes option pricing model, was $6.9 million. During the three months ended June 30, 2021, 234,390 of the options from this grant were forfeited as a result of the resignation of the Company’s former Co-CEO (see discussion below). In addition, in connection with the resignation, the Company accelerated the vesting of 184,932 options that were granted to the Company’s former Co-CEO in November 2019, and the remaining 648,401 unvested options from the November 2019 grant were forfeited. In connection with the accelerated vesting of the 184,932 options, the Company recorded $1.9 million of equity-based compensation expense, which is included in general and administrative expenses during the three and six months ended June 30, 2021 in the accompanying consolidated statements of operations. As previously announced, on April 13, 2021, the Company placed its then Co-Chief Executive Officer, Luke McGee, on unpaid leave while a matter relating to his past private activity was pending. On June 14, 2021, the Company and Mr. McGee agreed that Mr. McGee would resign from his positions as Co-CEO of the Company and a Director of the Company effective as of June 11, 2021. In connection with Mr. McGee’s resignation, the Company accelerated the vesting of certain unvested stock options as discussed above, and also accelerated the vesting of certain unvested shares of restricted stock as discussed below. Other than the accelerated vesting of the stock options and shares of restricted stock, and back pay paid to Mr. McGee relating to his unpaid base wages from April 13, 2021 to June 11, 2021, no other compensation was paid to Mr. McGee in connection with his resignation. The weighted-average assumptions used to determine the grant-date fair value of the stock options granted during the six months ended June 30, 2021 were as follows: ​ ​ ​ ​ ​ Expected volatility 44.5 % Risk-free interest rate 0.18 % Expected term 4.0 years Dividend yield ​ N/A ​ ​ During the three months ended June 30, 2021, 200,000 options were exercised resulting in $2.3 million of cash proceeds received by the Company during such period. The following table provides the activity regarding the Company’s outstanding stock options during the six months ended June 30, 2021 that were granted in connection with the 2019 Plan (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date ​ Weighted-Average ​ Weighted-Average ​ ​ Number of ​ ​ Fair Value ​ Exercise Price ​ Remaining ​ ​ Options ​ per Share ​ per Share ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 2.18 $ 11.56 ​ ​ Granted ​ 703 ​ $ 9.81 $ 48.72 ​ ​ Exercised ​ (216) ​ $ 2.43 $ 11.85 ​ ​ Forfeited ​ (914) ​ $ 6.34 $ 11.66 ​ ​ Outstanding, June 30, 2021 ​ 3,037 $ 3.31 $ 17.25 7.8 Years ​ Restricted Stock During the six months ended June 30, 2021, the Company granted 808,115 shares to various employees which vest ratably over the three or four-year periods following the grant dates, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $25.9 million. During the six months ended June 30, 2021, the Company granted 4,285 shares to non-employee consultants which vest over one year following the grant dates, subject to the consultants’ continuous service through the applicable vesting date. The grant-date fair value of these awards was $0.1 million. During the three months ended June 30, 2021, in connection with the resignation of the Company’s former Co-CEO, the Company accelerated the vesting of 22,192 shares of restricted stock that were granted in November 2019, and the remaining 77,808 unvested shares from the November 2019 grant were forfeited. In connection with the accelerated vesting of the 22,192 shares, the Company recorded $0.5 million of equity-based compensation expense, which is included in general and administrative expenses during the three and six months ended June 30, 2021 in the accompanying consolidated statements of operations. Activity related to the Company’s non-vested restricted stock grants for the six months ended June 30, 2021 is presented below (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance, December 31, 2020 ​ 2,248 $ 15.60 Granted ​ 812 ​ $ 32.10 Vested ​ (156) ​ $ 13.79 Forfeited ​ (568) ​ $ 16.49 Non-vested balance, June 30, 2021 ​ 2,336 ​ $ 21.27 ​ Incentive Units AdaptHealth Holdings granted Incentive Units in June 2019 (the 2019 Incentive Units) and in April 2018 (the 2018 Incentive Units) to certain members of management. The Incentive Units were intended to constitute profits interests and were granted for purposes of enabling such individuals to participate in the long-term growth and financial success of the Company and were issued in exchange for services to be performed. With respect to the 2019 Incentive Units, 50% of the awards were scheduled to vest in equal annual installments on each of the first four one-year Other Activity During the six months ended June 31, 2021, the Company granted 53,249 fully vested shares of Class A Common Stock to various employees of the Company, primarily newly hired employees. These shares had a grant-date fair value of $2.0 million, which was recognized as equity-based compensation expense during the six months ended June 30, 2021. Equity-Based Compensation Expense The Company recorded equity-based compensation expense of $7.4 million during the three months ended June 30, 2021, of which $5.7 million and $1.7 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $3.3 million during the three months ended June 30, 2020, of which $1.6 million and $1.7 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $16.0 million during the six months ended June 30, 2021, of which $11.1 million and $4.9 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $5.5 million during the six months ended June 30, 2020, of which $3.3 million and $2.2 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. At June 30, 2021, there was $39.3 million of unrecognized compensation expense related to equity-based compensation awards, which is expected to be recognized over a weighted-average period of 2.9 years.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2021
Earnings per share
Earnings (Loss) Per Share	(11) Earnings Per Share Earnings Per Share (EPS) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period on a basic and diluted basis. The Company calculates diluted earnings per share using the more dilutive of the treasury stock method and the two-class method after giving effect to all potential dilutive common stock. The Company’s potentially dilutive securities include potential common shares related to outstanding warrants, contingent consideration common shares, unvested restricted stock, outstanding stock options and outstanding preferred stock. Refer to Note 10, Stockholders’ Equity Diluted EPS considers the impact of potentially dilutive securities except when the potential common shares have an antidilutive effect. The Company’s outstanding preferred stock are considered participating securities, thus requiring the two-class method of computing EPS. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. Computations of basic and diluted net income (loss) per share were as follows (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Numerator ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) attributable to AdaptHealth Corp. ​ $ 79,107 ​ $ 4,470 ​ $ 75,141 ​ $ (30,081) Less: Earnings allocated to participating securities (1) ​ ​ 6,908 ​ ​ 119 ​ ​ 7,431 ​ ​ — Net income (loss) for basic EPS ​ $ 72,199 ​ $ 4,351 ​ $ 67,710 ​ $ (30,081) Change in fair value of warrant liability (2) ​ ​ (37,454) ​ ​ (654) ​ ​ (40,622) ​ ​ — Change in fair value of contingent consideration common shares liability (2) ​ ​ (18,357) ​ ​ (42) ​ ​ (19,991) ​ ​ — Net income (loss) for diluted EPS ​ $ 16,388 ​ $ 3,655 ​ $ 7,097 ​ $ (30,081) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator (1) (2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 129,664 ​ ​ 44,508 ​ ​ 120,438 ​ ​ 43,242 Add: Warrants (2) ​ ​ 2,554 ​ ​ 2,400 ​ ​ 2,736 ​ ​ — Add: Contingent Consideration Common Shares (2) ​ ​ 2,000 ​ ​ 350 ​ ​ 2,000 ​ ​ — Add: Stock options ​ ​ 1,533 ​ ​ — ​ ​ 1,641 ​ ​ — Add: Unvested restricted stock ​ ​ 831 ​ ​ 576 ​ ​ 905 ​ ​ — Diluted weighted-average common shares outstanding ​ ​ 136,582 ​ ​ 47,834 ​ ​ 127,720 ​ ​ 43,242 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share ​ $ 0.56 ​ $ 0.10 ​ $ 0.56 ​ $ (0.70) Diluted net income (loss) per share ​ $ 0.12 ​ $ 0.08 ​ $ 0.06 ​ $ (0.70) ​ (1) The Company’s preferred stock are considered participating securities. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were participating securities outstanding for all periods presented. There was no amount allocated to the participating securities during the six months ended June 30, 2020 due to the net loss recorded in that period. (2) For the three months ended June 30, 2021 and 2020, and the six months ended June 30, 2021, in accordance with the requirements of ASC Topic 260, Earnings per Share , the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability and the Company’s warrant liability are reversed from the numerator, and the corresponding securities are included in the denominator, for purposes of calculating diluted income per share as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the gains recorded for the changes in fair value of these instruments during those periods. For the six months ended June 30, 2020, the numerator and denominator for the diluted loss per share calculation is the same as used in the basic loss per share calculation and therefore exclude the effect of potential dilutive securities as their inclusion would have been anti-dilutive. Due to the Company reporting a net loss attributable to common stockholders for the six months ended June 30, 2020, all potentially dilutive securities related to outstanding warrants, contingent consideration common shares, unvested restricted stock, and outstanding stock options were excluded from the computation of diluted loss per share as their inclusion would have been anti-dilutive. The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in the Company’s calculation of diluted net income (loss) per share for the three and six months ended June 30, 2021 and 2020 because to do so would be antidilutive (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Preferred Stock ​ ​ 12,406 ​ ​ 1,216 ​ ​ 13,217 ​ ​ 608 Warrants ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,960 Stock Options ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ 883 Unvested restricted stock ​ ​ — ​ ​ — ​ ​ — ​ ​ 548 Contingent Consideration Common Shares ​ ​ — ​ ​ — ​ ​ — ​ ​ 350 Total ​ ​ 12,406 ​ ​ 2,296 ​ ​ 13,217 ​ ​ 4,349 ​

Lease Commitments

Lease Commitments	6 Months Ended
	Jun. 30, 2021
Lease Commitments
Lease Commitments	(12) Leases Capital Leases ​ The Company has acquired patient medical equipment and supplies, and office equipment through multiple capital leases. The capital lease obligations represent the present value of minimum lease payments under the respective agreement, payable monthly at various interest rates. Interest expense related to capital leases was less than $0.1 million for each of the three and six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021, future annual minimum payments required under lease obligations are as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 24,052 2023 ​ 269 2024 ​ ​ 22 Total ​ 24,343 Less amount representing interest ​ (122) ​ ​ 24,221 Current portion ​ (23,919) Long-term portion ​ $ 302 ​ At June 30, 2021 and December 31, 2020, equipment under capital leases consisted of patient equipment with a cost basis of approximately $40.4 million and $43.3 million, respectively, and accumulated depreciation of approximately $12.1 million and $13.0 million, respectively. Depreciation expense for equipment purchased under capital leases is primarily included in cost of net revenue in the accompanying consolidated statements of operations. ​ Operating Leases ​ The Company leases its office facilities and office equipment under noncancelable lease agreements which expire at various dates through March 2033. Some of these lease agreements include an option to renew at the end of the term. The Company also leases certain patient medical equipment with such leases set to expire at various dates through May 2022. The Company also leases certain office facilities on a month to month basis. In some instances, the Company is also required to pay its pro rata share of real estate taxes and utility costs in connection with the premises. Some of the leases contain fixed annual increases of minimum rent. Accordingly, the Company recognizes rent expense on a straight-line basis and records the difference between the recognized rent expense and the amount payable under the lease as deferred rent. The deferred rent recorded in accounts payable and accrued expenses on the accompanying consolidated balance sheets at June 30, 2021 and December 31, 2020 was $1.4 million and $1.4 million, respectively. The Company recorded rent expense of $9.1 million and $3.8 million for the three months ended June 30, 2021 and 2020, respectively. The Company recorded rent expense of $17.0 million and $7.3 million for the six months ended June 30, 2021 and 2020, respectively. These amounts are primarily included in cost of net revenue in the accompanying consolidated statements of operations. The minimum annual lease commitments under noncancelable leases with initial or remaining terms in excess of one year as of June 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 31,212 2023 ​ 25,466 2024 ​ 18,244 2025 ​ 11,274 2026 ​ 6,720 Thereafter ​ 13,978 Total minimum payments required (a) ​ $ 106,894 (a) Minimum payments have not been reduced by minimum sublease rentals of $3.2 million due in the future under noncancelable subleases. ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Taxes
Income Taxes	(13) Income Taxes On January 2, 2021, the Company completed a corporate restructuring to simplify its tax structure (the Tax Restructuring). In connection with the Tax Restructuring, on January 1, 2021, all remaining outstanding shares of Class B Common Stock, together with a corresponding number of New AdaptHealth Units, were exchanged for shares of Class A Common Stock. After these exchanges, AdaptHealth Holdings filed an entity classification election with the Internal Revenue Service, electing to be treated as a taxable corporation for U.S. federal income tax purposes effective January 2, 2021. As a result of the Business Combination and prior to the Tax Restructuring, the Company was subject to U.S. federal, state, and local income taxes with respect to its allocable share of any taxable income or loss of AdaptHealth Holdings. AdaptHealth Holdings was treated as a partnership for U.S. income tax purposes and generally did not pay income taxes in most jurisdictions. Instead, AdaptHealth Holdings’ taxable income or loss was passed through to its members, including the Company. Additionally, the Company was subject to U.S. federal, state, and local income taxes on the taxable income or loss of the underlying C-corporations in the AdaptHealth group where taxes are paid at the entity level. As a result of the Tax Restructuring, the Company is subject to U.S. federal, state, and local income taxes on materially all of its earnings. For the three months ended June 30, 2021 and 2020, the Company recorded income tax expense of $12.3 million and $1.8 million, respectively. For the six months ended June 30, 2021 and 2020, the Company recorded income tax expense of $10.6 million and $0.2 million, respectively. As of June 30, 2021 and December 31, 2020, the Company had an unrecognized tax benefit of $1.9 million. Tax Receivable Agreement ​ AdaptHealth Corp. is party to a Tax Receivable Agreement (TRA) with certain current and former members of AdaptHealth Holdings. The TRA provides for the payment by AdaptHealth Corp. of 85% of the tax savings, if any, that AdaptHealth Corp. realizes (or is deemed to realize in certain circumstances) as a result of (i) certain increases in tax basis resulting from exchanges of New AdaptHealth Units and shares of Class B Common Stock; (ii) certain tax attributes of the corresponding sellers existing prior to an exchange; (iii) imputed interest deemed to be paid by AdapthHealth Corp. as a result of payments it makes under the TRA; and (iv) certain increases in tax basis resulting from payments AdaptHealth Corp. makes under the TRA. ​ During the six months ended June 30, 2021, the Company increased its TRA liability through an aggregate $146.5 million reduction in additional paid-in capital resulting from additional exchanges of New AdaptHealth Units and shares of Class B Common Stock. Correspondingly, during the six months ended June 30, 2021, the Company increased its deferred tax asset by $163.3 million through an increase in additional paid-in-capital resulting from these exchanges and other increases of AdaptHealth Corp.’s ownership interest in AdaptHealth Holdings. ​ At June 30, 2021 and December 31, 2020, the Company had a liability recorded relating to the TRA of $300.1 million and $152.0 million, respectively, which is included in other long-term liabilities in the accompanying consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies.
Commitments and Contingencies	(14) Commitments and Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies any liability that may ultimately result from resolution of such loss contingencies will not have a material adverse effect on the Company’s financial conditions or results of operations. However, the Company’s assessment may be affected by limited information. Accordingly, the Company’s assessment may change in the future based upon availability of new information and further developments in the proceedings of such matters. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. ​ In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS), in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five-year term which expires in April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject to the requirements of the CIA following the acquisition. On January 17, 2021, the OIG notified PPS that its report for the period ended March 31, 2020 had been accepted and PPS had satisfied its obligations under the CIA as of such date. ​ The Company and certain of its officers were named as defendants in a lawsuit, as described below. The Company cannot reasonably predict the outcome of this legal proceeding, nor can it estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in this proceeding could have a material adverse effect on the Company’s results of operations, cash flows or financial condition. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. ​ On July 29, 2021, Robert Charles Faille Jr., a purported shareholder of the Company, filed a purported class action complaint against the Company and certain of its officers in the United States District Court for the Eastern District of Pennsylvania (the Complaint). The Complaint purports to be asserted on behalf of a class of persons who purchased the Company’s stock between November 11, 2019 and July 16, 2021. The Complaint generally alleges that the Company and certain of its officers violated federal securities laws by making allegedly false and misleading statements and/or failing to disclose material information regarding the Company’s organic growth trajectory. The Complaint seeks unspecified damages. The Company intends to vigorously defend against the allegations contained in the Complaint, but there can be no assurance that the defense will be successful. ​

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions
Related Party Transactions	(15) Related Party Transaction The Company and one of its executive officers and shareholders own an equity interest in a vendor of the Company that provides automated order intake software. The individual’s equity ownership is less than 1%. The expense related to this vendor was $1.2 million and $0.6 million for the three months ended June 30, 2021 and 2020, respectively. The expense related to this vendor was $2.2 million and $1.1 million for the six months ended June 30, 2021 and 2020, respectively. The Company accounts for this investment under the cost method of accounting based on its level of equity ownership. ​

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	(16) Subsequent Events Subsequent to June 30, 2021, the Company acquired several home medical equipment businesses. The total consideration included cash payments of $124.4 million at closing, and the issuance of a total of 976,819 shares of the Company’s Class A Common Stock at closing. Due to the timing of these acquisitions, as of the date the consolidated interim financial statements were available to be issued, the Company was in the process of determining the allocation of the fair value of the consideration paid to the fair value of the net assets acquired and a preliminary allocation has not yet been determined. ​

General Information (Policies)

General Information (Policies)	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation	(a) Basis of Presentation The consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the consolidated interim financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented. The Business Combination was accounted for as a reverse recapitalization, with DFB treated as the acquired company and AdaptHealth Holdings as the acquirer, for financial reporting purposes. Therefore, the equity structure has been restated to that of the Company. As of June 30, 2021, the Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the Securities Act), as modified by the Jumpstart our Business Startups Act of 2012, (the JOBS Act), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more during such fiscal year, (iii) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock in the IPO, which would be December 31, 2023. The Company will no longer qualify as an emerging growth company as of December 31, 2021 due to the market value of its Common Stock that was held by non-affiliates as of June 30, 2021.
Basis of Consolidation	(b) Basis of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Concentration of Credit Risk	(c) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.
Accounting Estimates	(d) Accounting Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, contingent consideration, equity-based compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates.
Valuation of Goodwill	(e) Valuation of Goodwill The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is tested for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment review of goodwill during the fourth quarter of each year. The impairment testing can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform quantitative goodwill impairment testing. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any.
Impairment of Long Lived Assets	(f) Impairment of Long Lived Assets The Company’s long lived assets, such as equipment and other fixed assets and definite-lived identifiable intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. These assets are tested for impairment consistent with the Company’s long-lived assets. The following table summarizes the useful lives of the identifiable intangible assets acquired: ​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years ​ The Company did not incur any impairment charges on long-lived assets for the three and six months ended June 30, 2021 and 2020. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long lived assets.
Business segment	(g) Business Segment The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure.
Recent Accounting Pronouncements	(h) Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which requires lessees to recognize leases on its-balance sheet and disclose key information about leasing arrangements. Under the new guidance, lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on the balance sheet for most leases. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The Company expects to elect the “package of practical expedients” under the new standard, which, among other things, permits lease agreements that are twelve months or less to be excluded from the balance sheet, and permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company will adopt the new standard during the year ended December 31, 2021. The Company expects to adopt this guidance using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application, and will recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company expects that this standard will have a material effect on its consolidated financial statements. While the Company continues to assess all of the effects of the adoption, it currently estimates that upon adoption it will record approximately $88 million to $98 million of operating lease liabilities on its consolidated balance sheet, with a corresponding ROU asset, based on the present value of the remaining minimum rental payments under the current leasing standard for existing operating leases. This amount is estimated as of the date of initial application ( January 1, 2021 ), and will be impacted by changes to the existing operating leases during 2021 for new leases, lease amendments, lease terminations and acquisitions. The Company does not expect the adoption will have an impact on its accounting for existing capital leases. The adoption will also require significant new disclosures about the Company’s leasing activities. Additionally, the Company estimates that it will record approximately $55 million to $65 million of operating lease liabilities on its consolidated balance sheet, with a corresponding ROU asset , based on the present value of the remaining minimum rental payments under the current leasing standard for operating leases acquired by the Company in connection with the acquisition of AeroCare Holdings, Inc. (AeroCare) on February 1, 2021 (note 3). The Company is implementing a lease management system to track and record the lease liabilities and ROU asset for all leases with a term of greater than 12 months. The Company is also in the process of completing additional process changes and updating internal controls to ensure the new reporting and disclosure requirements are met upon adoption. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ​ In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848)
Reclassifications	(i) Reclassifications ​ Certain prior year amounts have been reclassified to conform to the current year presentation.

General Information (Tables)

General Information (Tables)	6 Months Ended
	Jun. 30, 2021
General Information
Schedule of useful lives of acquired intangible assets	​ ​ ​ ​ ​ Tradenames 5 10 ​ years Payor contracts 10 ​ years Contractual rental agreements 2 ​ years Developed technology 5 ​ years

Revenue Recognition and Accou_2

Revenue Recognition and Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of composition of net revenues by payor type and core service lines	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Insurance ​ $ 371,869 ​ $ 148,165 ​ $ 661,879 ​ $ 262,616 Government ​ ​ 177,323 ​ ​ 60,513 ​ ​ 311,053 ​ ​ 111,758 Patient pay ​ 67,825 ​ 23,438 ​ 126,204 ​ 49,181 Net revenue ​ $ 617,017 ​ $ 232,116 ​ $ 1,099,136 ​ $ 423,555 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Net sales revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 163,331 ​ $ 84,421 ​ $ 292,013 ​ $ 153,315 Diabetes ​ ​ 123,314 ​ ​ 6,372 ​ ​ 218,331 ​ ​ 11,679 Supplies to the home ​ ​ 42,675 ​ ​ 27,868 ​ ​ 84,038 ​ ​ 55,900 Respiratory ​ 13,154 ​ 18,114 ​ 18,775 ​ 20,882 HME ​ ​ 30,360 ​ ​ 12,727 ​ ​ 54,516 ​ ​ 24,306 Other ​ ​ 27,763 ​ ​ 11,463 ​ ​ 50,189 ​ ​ 23,856 Total net sales revenue ​ $ 400,597 ​ $ 160,965 ​ $ 717,862 ​ $ 289,938 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenue from fixed monthly equipment reimbursements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 66,335 ​ $ 22,644 ​ $ 114,444 ​ $ 45,313 Diabetes ​ ​ 3,216 ​ ​ — ​ ​ 6,069 ​ ​ — Respiratory ​ 111,528 ​ 30,856 ​ 194,982 ​ 55,863 HME ​ ​ 24,431 ​ ​ 13,262 ​ ​ 44,811 ​ ​ 25,439 Other ​ ​ 10,910 ​ ​ 4,389 ​ ​ 20,968 ​ ​ 7,002 Total net revenue from fixed monthly equipment reimbursements ​ $ 216,420 ​ $ 71,151 ​ $ 381,274 ​ $ 133,617 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total net revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Sleep ​ $ 229,666 ​ $ 107,065 ​ $ 406,457 ​ $ 198,628 Diabetes ​ ​ 126,530 ​ ​ 6,372 ​ ​ 224,400 ​ ​ 11,679 Supplies to the home ​ ​ 42,675 ​ ​ 27,868 ​ ​ 84,038 ​ ​ 55,900 Respiratory ​ 124,682 ​ 48,970 ​ 213,757 ​ 76,745 HME ​ ​ 54,791 ​ ​ 25,989 ​ ​ 99,327 ​ ​ 49,745 Other ​ ​ 38,673 ​ ​ 15,852 ​ ​ 71,157 ​ ​ 30,858 Total net revenue ​ $ 617,017 ​ $ 232,116 ​ $ 1,099,136 ​ $ 423,555

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2021
Business Acquisition
Schedule of proforma net revenue and operating income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 631,568 ​ $ 572,298 ​ $ 1,224,287 ​ $ 1,102,997 Operating income ​ $ 66,964 ​ $ 55,719 ​ $ 92,600 ​ $ 96,957
Summary of results of business acquired	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 Net revenue ​ $ 248,209 ​ $ 53,002 ​ $ 390,856 ​ $ 93,727 Operating income (loss) ​ $ 37,306 ​ $ (2,061) ​ $ 57,689 ​ $ (7,621)
Significant Acquisitions In 2021 [Member]
Business Acquisition
Summary of consideration	​ ​ ​ ​ ​ Cash consideration ​ $ 1,325,133 Equity consideration ​ 1,235,693 Contingent consideration ​ ​ 1,000 Deferred payments ​ 983 Total ​ $ 2,562,809
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ Cash ​ $ 31,944 Accounts receivable ​ 97,523 Inventory ​ 39,525 Prepaid and other current assets ​ 4,828 Equipment and other fixed assets ​ 179,761 Goodwill ​ 2,254,990 Identifiable intangible assets ​ ​ 142,000 Other assets ​ ​ 1,194 Deferred tax liabilities ​ ​ (63,222) Accounts payable and accrued expenses ​ (96,325) Contract liabilities ​ ​ (14,583) Other current liabilities ​ ​ (11,576) Other long-term liabilities ​ ​ (1,055) Capital lease obligations ​ (2,195) Net assets acquired ​ $ 2,562,809
Significant Acquisitions In 2020 [Member]
Business Acquisition
Summary of consideration	​ ​ ​ ​ ​ Cash consideration ​ $ 108,199 Equity consideration ​ 6,248 Deferred payments ​ ​ 33 Total ​ $ 114,480
Summary of estimated fair values of the net assets acquired	​ ​ ​ ​ ​ Cash ​ $ 736 Accounts receivable ​ 20,118 Inventory ​ 4,413 Prepaid and other current assets ​ 1,334 Equipment and other fixed assets ​ 25,264 Goodwill ​ 76,060 Accounts payable and accrued expenses ​ (6,493) Contract liabilities ​ ​ (3,906) Other liabilities ​ ​ (1,419) Capital lease obligations ​ ​ (1,627) Net assets acquired ​ $ 114,480

Equipment and Other Fixed Ass_2

Equipment and Other Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Equipment and Other Fixed Assets
Schedule of equipment and other fixed assets	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Patient medical equipment ​ $ 379,683 $ 158,108 Delivery vehicles ​ 21,666 8,211 Other ​ 42,409 26,098 ​ ​ 443,758 ​ 192,417 Less accumulated depreciation ​ (134,687) ​ (81,949) ​ ​ $ 309,071 ​ $ 110,468

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill.
Schedule of change in the carrying amount of goodwill	​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 998,810 Goodwill from acquisitions ​ ​ 2,254,990 Net cash receipts relating to prior acquisitions ​ ​ (558) Reduction ​ ​ (22,042) Balance at June 30, 2021 ​ $ 3,231,200
Schedule of identifiable intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $6,711 ​ $ 98,889 ​ 9.2 Payor contracts, net of accumulated amortization of $7,716 ​ ​ 74,284 ​ 9.1 Contractual rental agreements, net of accumulated amortization of $14,583 ​ ​ 55,417 ​ 1.8 Developed technology, net of accumulated amortization of $1,260 ​ ​ 5,040 ​ 4.0 Identifiable intangible assets, net ​ $ 233,630 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ Remaining Life (Years) Tradenames, net of accumulated amortization of $1,793 ​ $ 32,007 ​ 8.8 Payor contracts, net of accumulated amortization of $3,616 ​ ​ 78,384 ​ 9.6 Developed technology, net of accumulated amortization of $630 ​ ​ 5,670 ​ 4.5 Identifiable intangible assets, net ​ $ 116,061 ​ ​
Schedule of future amortization expense related to identifiable intangible assets	​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 55,876 2023 ​ 41,293 2024 ​ 20,876 2025 ​ 20,817 2026 ​ 18,720 Thereafter ​ 76,048 Total ​ $ 233,630

Fair Value of Assets and Liab_2

Fair Value of Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Business Acquisition, Contingent Consideration [Line Items]
Summary of financial assets and liabilities measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 58 ​ $ — ​ $ — Total assets measured at fair value ​ $ 58 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 20,004 Acquisition-related contingent consideration-long term ​ — ​ — ​ 1,568 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,938 ​ ​ — Interest rate swap agreements-long term ​ — ​ 6,240 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 25,758 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 20,675 Warrant liability ​ ​ — ​ ​ — ​ ​ 73,283 Total liabilities measured at fair value ​ $ — ​ $ 12,178 ​ $ 141,288 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ Money market accounts ​ $ 5,602 ​ $ — ​ $ — Total assets measured at fair value ​ $ 5,602 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ Acquisition-related contingent consideration-short term ​ $ — ​ $ — ​ $ 23,941 Acquisition-related contingent consideration-long term ​ — ​ — ​ 9,599 Interest rate swap agreements-short term ​ ​ — ​ ​ 5,941 ​ ​ — Interest rate swap agreements-long term ​ — ​ 10,220 ​ — Contingent consideration common shares liability-short term ​ ​ — ​ ​ — ​ ​ 36,846 Contingent consideration common shares liability-long term ​ ​ — ​ ​ — ​ ​ 33,631 Warrant liability ​ ​ — ​ ​ — ​ ​ 113,905 Total liabilities measured at fair value ​ $ — ​ $ 16,161 ​ $ 217,922
Summary of non-financial assets measured on a non-recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Assets: ​ ​ ​ Goodwill (Level 3) ​ $ 3,231,200 ​ $ 998,810 Identifiable intangible assets, net (Level 3) ​ $ 233,630 ​ $ 116,061
Acquisition Related Contingent Consideration [Member]
Business Acquisition, Contingent Consideration [Line Items]
Reconciliation of contingent consideration liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 33,540 ​ $ 1,000 ​ $ (13,396) ​ $ 255 ​ $ 173 ​ $ 21,572 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2020 ​ Beginning Balance Additions Payments Change in Fair Value Other activity Ending Balance Contingent consideration - Level 3 liabilities ​ $ 14,725 ​ $ — ​ $ (1,000) ​ $ (2,900) $ — ​ $ 10,825

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities
Summary of fair value of derivative financial instruments as well as their classification on the consolidated balance sheets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ Balance Sheet Location ​ Asset (Liability) Interest rate swap agreements ​ Other current liabilities ​ $ (5,938) ​ $ (5,941) Interest rate swap agreements ​ Other long-term liabilities ​ (6,240) ​ (10,220) Total ​ ​ ​ $ (12,178) ​ $ (16,161) ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Accounts Payable and Accrued Expenses
Schedule of components accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 ​ 2020 Accounts payable ​ $ 260,580 $ 191,038 Employee-related accruals ​ 42,854 ​ 26,705 Accrued interest ​ 24,974 ​ 11,062 Other ​ 22,306 ​ 25,407 Total ​ $ 350,714 ​ $ 254,212

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt
Schedule of summary of long term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 ​ 2020 Secured term loans ​ $ 800,000 $ 248,438 Revolving credit facility ​ ​ 175,000 ​ ​ 55,000 Senior unsecured notes ​ ​ 850,000 ​ ​ 350,000 Note payable ​ 71,750 ​ 143,500 Other ​ — ​ 333 Unamortized deferred financing fees ​ (23,674) ​ (12,557) ​ ​ 1,873,076 ​ 784,714 Current portion ​ (96,750) ​ (8,146) Long-term portion ​ $ 1,776,326 ​ $ 776,568

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Business Acquisition
Schedule of changes in warrant liability	​ ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2020 ​ $ 113,905 Change in estimated fair value of the warrant liability ​ ​ (40,622) Estimated fair value of warrant liability at June 30, 2021 ​ $ 73,283 ​ ​ ​ ​ Estimated fair value of warrant liability at December 31, 2019 ​ $ 27,635 Change in estimated fair value of the warrant liability ​ ​ 35,446 Reclassification of warrant liability to equity for exercised warrants ​ (21,019) Estimated fair value of warrant liability at June 30, 2020 ​ $ 42,062
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Grant Date ​ Weighted-Average ​ Weighted-Average ​ ​ Number of ​ ​ Fair Value ​ Exercise Price ​ Remaining ​ ​ Options ​ per Share ​ per Share ​ Contractual Term Outstanding, December 31, 2020 ​ 3,464 ​ $ 2.18 $ 11.56 ​ ​ Granted ​ 703 ​ $ 9.81 $ 48.72 ​ ​ Exercised ​ (216) ​ $ 2.43 $ 11.85 ​ ​ Forfeited ​ (914) ​ $ 6.34 $ 11.66 ​ ​ Outstanding, June 30, 2021 ​ 3,037 $ 3.31 $ 17.25 7.8 Years
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares of ​ ​ Weighted-Average Grant Date ​ ​ Restricted Stock ​ Fair Value per Share Non-vested balance, December 31, 2020 ​ 2,248 $ 15.60 Granted ​ 812 ​ $ 32.10 Vested ​ (156) ​ $ 13.79 Forfeited ​ (568) ​ $ 16.49 Non-vested balance, June 30, 2021 ​ 2,336 ​ $ 21.27
Common Shares Liability
Business Acquisition
Reconciliation of contingent consideration liabilities	​ ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2020 ​ $ 70,477 Change in estimated fair value of the contingent consideration common shares liability ​ ​ (24,044) Estimated fair value of contingent consideration common shares liability at June 30, 2021 ​ $ 46,433 ​ ​ ​ ​ Estimated fair value of contingent consideration common shares liability at December 31, 2019 ​ $ 9,316 Change in estimated fair value of the contingent consideration common shares liability ​ 16,325 Estimated fair value of contingent consideration common shares liability at June 30, 2020 ​ $ 25,641
Options
Business Acquisition
Schedule of assumptions used to determine the grant date fair value	​ ​ ​ ​ ​ Expected volatility 44.5 % Risk-free interest rate 0.18 % Expected term 4.0 years Dividend yield ​ N/A ​

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings per share
Schedule of calculation of basic and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Numerator ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) attributable to AdaptHealth Corp. ​ $ 79,107 ​ $ 4,470 ​ $ 75,141 ​ $ (30,081) Less: Earnings allocated to participating securities (1) ​ ​ 6,908 ​ ​ 119 ​ ​ 7,431 ​ ​ — Net income (loss) for basic EPS ​ $ 72,199 ​ $ 4,351 ​ $ 67,710 ​ $ (30,081) Change in fair value of warrant liability (2) ​ ​ (37,454) ​ ​ (654) ​ ​ (40,622) ​ ​ — Change in fair value of contingent consideration common shares liability (2) ​ ​ (18,357) ​ ​ (42) ​ ​ (19,991) ​ ​ — Net income (loss) for diluted EPS ​ $ 16,388 ​ $ 3,655 ​ $ 7,097 ​ $ (30,081) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Denominator (1) (2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 129,664 ​ ​ 44,508 ​ ​ 120,438 ​ ​ 43,242 Add: Warrants (2) ​ ​ 2,554 ​ ​ 2,400 ​ ​ 2,736 ​ ​ — Add: Contingent Consideration Common Shares (2) ​ ​ 2,000 ​ ​ 350 ​ ​ 2,000 ​ ​ — Add: Stock options ​ ​ 1,533 ​ ​ — ​ ​ 1,641 ​ ​ — Add: Unvested restricted stock ​ ​ 831 ​ ​ 576 ​ ​ 905 ​ ​ — Diluted weighted-average common shares outstanding ​ ​ 136,582 ​ ​ 47,834 ​ ​ 127,720 ​ ​ 43,242 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share ​ $ 0.56 ​ $ 0.10 ​ $ 0.56 ​ $ (0.70) Diluted net income (loss) per share ​ $ 0.12 ​ $ 0.08 ​ $ 0.06 ​ $ (0.70) ​ (1) The Company’s preferred stock are considered participating securities. Calculation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were participating securities outstanding for all periods presented. There was no amount allocated to the participating securities during the six months ended June 30, 2020 due to the net loss recorded in that period. (2) For the three months ended June 30, 2021 and 2020, and the six months ended June 30, 2021, in accordance with the requirements of ASC Topic 260, Earnings per Share , the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability and the Company’s warrant liability are reversed from the numerator, and the corresponding securities are included in the denominator, for purposes of calculating diluted income per share as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the gains recorded for the changes in fair value of these instruments during those periods. For the six months ended June 30, 2020, the numerator and denominator for the diluted loss per share calculation is the same as used in the basic loss per share calculation and therefore exclude the effect of potential dilutive securities as their inclusion would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Six Months Ended June 30, ​ ​ 2021 ​ 2020 2021 ​ 2020 Preferred Stock ​ ​ 12,406 ​ ​ 1,216 ​ ​ 13,217 ​ ​ 608 Warrants ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,960 Stock Options ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ 883 Unvested restricted stock ​ ​ — ​ ​ — ​ ​ — ​ ​ 548 Contingent Consideration Common Shares ​ ​ — ​ ​ — ​ ​ — ​ ​ 350 Total ​ ​ 12,406 ​ ​ 2,296 ​ ​ 13,217 ​ ​ 4,349

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Lease Commitments
Summary of future annual minimum payments required under lease obligations	​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 24,052 2023 ​ 269 2024 ​ ​ 22 Total ​ 24,343 Less amount representing interest ​ (122) ​ ​ 24,221 Current portion ​ (23,919) Long-term portion ​ $ 302
Summary of minimum annual lease commitments under noncancelable leases	​ ​ ​ ​ ​ Twelve months ending June 30, ​ ​ 2022 ​ $ 31,212 2023 ​ 25,466 2024 ​ 18,244 2025 ​ 11,274 2026 ​ 6,720 Thereafter ​ 13,978 Total minimum payments required (a) ​ $ 106,894 (a) Minimum payments have not been reduced by minimum sublease rentals of $3.2 million due in the future under noncancelable subleases.

General Information (Details)

General Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Impairment of long-lived assets	$ 0	$ 0	$ 0	$ 0
Payor contracts
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years
Contractual rental agreements
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			2 years
Developed technology
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			5 years
Minimum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			5 years
Maximum | Tradenames [Member]
Property, Plant and Equipment [Line Items]
Finite-Lived Intangible Asset, Useful Life			10 years

General Information - Leases (D

General Information - Leases (Details) - Pro Forma [Member] - Cumulative Effect, Period of Adoption, Adjustment [Member] - USD ($) $ in Millions	Jan. 31, 2021	Dec. 31, 2020
Minimum
Recently Adopted Accounting Pronouncements
Operating Lease, Liability		$ 88
Operating Lease, Right-of-Use Asset		88
Maximum
Recently Adopted Accounting Pronouncements
Operating Lease, Liability		98
Operating Lease, Right-of-Use Asset		$ 98
AeroCare Holdings [Member] | Minimum
Recently Adopted Accounting Pronouncements
Operating Lease, Liability	$ 55
Operating Lease, Right-of-Use Asset	55
AeroCare Holdings [Member] | Maximum
Recently Adopted Accounting Pronouncements
Operating Lease, Liability	65
Operating Lease, Right-of-Use Asset	$ 65

Revenue Recognition and Accou_3

Revenue Recognition and Accounts Receivable (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Jul. 31, 2020
Revenue Recognition
Total net revenues		$ 617,017	$ 232,116	$ 1,099,136	$ 423,555
Recoupable Advance Payment, CARES Act	$ 45,800
CARES Act funding recouped		15,900
CARES Act deferred payments		33,600		33,600
Unbilled revenue		18,300		18,300		$ 20,200
Significant Acquisitions In 2021 [Member]
Revenue Recognition
CARES Act deferred payments							$ 3,700
Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		400,597	160,965	717,862	289,938
Transferred over Time [Member]
Revenue Recognition
Total net revenues		216,420	71,151	381,274	133,617
Sleep
Revenue Recognition
Total net revenues		229,666	107,065	406,457	198,628
Sleep | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		163,331	84,421	292,013	153,315
Sleep | Transferred over Time [Member]
Revenue Recognition
Total net revenues		66,335	22,644	114,444	45,313
Diabetes [Member]
Revenue Recognition
Total net revenues		126,530	6,372	224,400	11,679
Diabetes [Member] | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		123,314	6,372	218,331	11,679
Diabetes [Member] | Transferred over Time [Member]
Revenue Recognition
Total net revenues		3,216		6,069
Supplies to the home
Revenue Recognition
Total net revenues		42,675	27,868	84,038	55,900
Supplies to the home | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		42,675	27,868	84,038	55,900
Respiratory
Revenue Recognition
Total net revenues		124,682	48,970	213,757	76,745
Respiratory | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		13,154	18,114	18,775	20,882
Respiratory | Transferred over Time [Member]
Revenue Recognition
Total net revenues		111,528	30,856	194,982	55,863
HME
Revenue Recognition
Total net revenues		54,791	25,989	99,327	49,745
HME | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		30,360	12,727	54,516	24,306
HME | Transferred over Time [Member]
Revenue Recognition
Total net revenues		24,431	13,262	44,811	25,439
Other
Revenue Recognition
Total net revenues		38,673	15,852	71,157	30,858
Other | Transferred at Point in Time [Member]
Revenue Recognition
Total net revenues		27,763	11,463	50,189	23,856
Other | Transferred over Time [Member]
Revenue Recognition
Total net revenues		10,910	4,389	20,968	7,002
Insurance Payor [Member]
Revenue Recognition
Total net revenues		371,869	148,165	661,879	262,616
Government payor
Revenue Recognition
Total net revenues		177,323	60,513	311,053	111,758
Patient payor
Revenue Recognition
Total net revenues		$ 67,825	$ 23,438	$ 126,204	$ 49,181

Acquisitions (Details)

Acquisitions (Details) $ / shares in Units, $ in Thousands	Jun. 01, 2021USD ($)shares	Apr. 30, 2021USD ($)shares	Feb. 01, 2021USD ($)$ / sharesshares	Mar. 02, 2020USD ($)	Jan. 02, 2020USD ($)	Jul. 31, 2021USD ($)shares	Jun. 30, 2021USD ($)itemshares	Jun. 30, 2020USD ($)shares	Mar. 18, 2021shares	Dec. 31, 2020USD ($)shares	Nov. 08, 2019$ / shares
Business Acquisition
Deferred purchase price in connection with acquisitions							$ 983	$ 33
Preferred Stock, Shares Issued | shares							124,060			163,560
Exercise price | $ / shares											$ 11.50
Estimated fair values of net assets acquired
Goodwill							$ 3,231,200			$ 998,810
Additional consideration from adjustment							(558)
Series C Preferred Stock [Member]
Estimated fair values of net assets acquired
Preferred stock, liquidation preference (in dollars per share) | $ / shares			$ 0.0001
Shares of common stock received in conversion for each share of preferred stock | shares									100
Significant Acquisitions In 2021 [Member]
Business Acquisition
Cash payment							1,325,133
Deferred purchase price in connection with acquisitions							983
Estimated fair values of net assets acquired
Cash							31,944
Accounts receivable							97,523
Inventory							39,525
Prepaid and other current assets							4,828
Equipment and other fixed assets							179,761
Other assets							1,194
Identifiable intangible assets							142,000
Goodwill							2,254,990
Accounts payable and accrued expenses							(96,325)
Contract liabilities							(14,583)
Net liabilities - working capital							(11,576)
Other long-term liabilities							(1,055)
Capital lease obligations							(2,195)
Deferred tax liability							(63,222)
Net assets acquired							2,562,809
Total Merger Consideration							$ 2,562,809
AeroCare Holdings [Member]
Business Acquisition
Interest acquired, as a percent			100.00%
Cash payment			$ 1,100,000
Options issued in acquisition, in shares | shares			3,959,892
Exercise price | $ / shares			$ 6.24
Weighted average exercise period			7 years
Estimated fair values of net assets acquired
Cash			$ 27,700
Accounts receivable			75,900
Inventory			27,600
Equipment and other fixed assets			163,500
Identifiable intangible assets			138,200
Goodwill			2,100
Accounts payable and accrued expenses			(82,700)
Net liabilities - working capital			(20,900)
Deferred tax liability			(63,700)
AeroCare Holdings [Member] | Subsequent Event
Estimated fair values of net assets acquired
Additional consideration from adjustment						$ 4,100
AeroCare Holdings [Member] | Contractual rental agreements
Estimated fair values of net assets acquired
Identifiable intangible assets			70,000
AeroCare Holdings [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets			$ 68,200
AeroCare Holdings [Member] | Class A Common Stock
Business Acquisition
Issuance of stock for acquisitions (in shares) | shares			13,992,615
AeroCare Holdings [Member] | Series C Preferred Stock [Member]
Business Acquisition
Preferred Stock, Shares Issued | shares			130,474.73
Spiro Health Services [Member]
Business Acquisition
Interest acquired, as a percent		100.00%
Cash payment		$ 66,100
Issuance of stock for acquisitions (in shares) | shares		244,641
Estimated fair values of net assets acquired
Cash		$ 2,100
Accounts receivable		7,300
Inventory		4,900
Net assets - working capital		200
Equipment and other fixed assets		2,200
Identifiable intangible assets		1,000
Goodwill		63,800
Accounts payable and accrued expenses		(5,100)
Capital lease obligations		(2,200)
Maximum potential contingent consideration		$ 1,000
Healthy Living Medical Supply, L L C [Member]
Business Acquisition
Interest acquired, as a percent	100.00%
Cash payment	$ 47,000
Issuance of stock for acquisitions (in shares) | shares	196,779
Estimated fair values of net assets acquired
Cash	$ 600
Accounts receivable	7,500
Inventory	2,900
Net assets - working capital	200
Equipment and other fixed assets	1,500
Identifiable intangible assets	1,300
Goodwill	41,700
Accounts payable and accrued expenses	$ (3,600)
Home Medical Equipment Providers, Equity Interests And Assets Acquisitions [Member]
Business Acquisition
Interest acquired, as a percent							100.00%
Number of home medical equipment providers acquired | item							2
Number of entities acquired | item							3
Number of acquisitions including contingent consideration | item							1
Cash payment							$ 57,500
Issuance of stock for acquisitions (in shares) | shares							99,695
Estimated fair values of net assets acquired
Cash							$ 1,500
Accounts receivable							6,400
Inventory							3,800
Equipment and other fixed assets							12,000
Goodwill							41,200
Accounts payable and accrued expenses							(4,700)
Net liabilities - working capital							(200)
Maximum potential contingent consideration							4,000
Additional consideration from adjustment							900
Home Medical Equipment Providers, Equity Interests And Assets Acquisitions [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets							1,500
Other
Business Acquisition
Cash payment							4,900
Deferred purchase price in connection with acquisitions							1,000
Estimated fair values of net assets acquired
Accounts receivable							400
Inventory							200
Equipment and other fixed assets							700
Goodwill							4,900
Accounts payable and accrued expenses							(200)
Net liabilities - working capital							(100)
Other | Subsequent Event
Business Acquisition
Cash payment						$ 124,400
Issuance of stock for acquisitions (in shares) | shares						976,819
Significant Acquisitions In 2020 [Member]
Business Acquisition
Cash payment								108,199
Deferred purchase price in connection with acquisitions								33
Estimated fair values of net assets acquired
Cash								736
Accounts receivable								20,118
Inventory								4,413
Prepaid and other current assets								1,334
Equipment and other fixed assets								25,264
Goodwill								76,060
Accounts payable and accrued expenses								(6,493)
Contract liabilities								(3,906)
Unfavorable lease liability								(1,419)
Capital lease obligations								(1,627)
Net assets acquired								114,480
Total Merger Consideration								114,480
Additional consideration from adjustment							(600)
Patient Care Solutions (PCS) [Member]
Business Acquisition
Interest acquired, as a percent					100.00%
Cash payment					$ 15,000
Estimated fair values of net assets acquired
Accounts receivable								16,300
Equipment and other fixed assets								500
Goodwill								1,400
Net liabilities - working capital								(3,200)
Advanced Home Care Inc [Member]
Business Acquisition
Cash payment				$ 58,500
Estimated fair values of net assets acquired
Net assets - working capital								500
Equipment and other fixed assets								18,400
Goodwill								39,600
Maximum potential contingent consideration						$ 5,000	$ 5,000	$ 9,000
Home Medical Equipment Provider Acquired In 2020 [Member]
Business Acquisition
Interest acquired, as a percent								100.00%
Cash payment								$ 32,400
Issuance of stock for acquisitions (in shares) | shares								386,874
Estimated fair values of net assets acquired
Cash								$ 300
Accounts receivable								3,300
Inventory								1,400
Equipment and other fixed assets								5,900
Goodwill								33,700
Accounts payable and accrued expenses								(2,900)
Net liabilities - working capital								(1,400)
Capital lease obligations								(1,600)
Other acquisitions in 2020
Business Acquisition
Cash payment								2,200
Estimated fair values of net assets acquired
Cash								400
Accounts receivable								500
Inventory								300
Equipment and other fixed assets								400
Goodwill								1,400
Accounts payable and accrued expenses								(700)
Net liabilities - working capital								(100)
Other acquisitions in 2020 | Maximum
Business Acquisition
Deferred purchase price in connection with acquisitions								$ 100

Acquisitions - Consideration an

Acquisitions - Consideration and Allocation (Details) - USD ($) $ in Thousands	Feb. 01, 2021	Mar. 02, 2020	Jan. 02, 2020	Jun. 30, 2021	Jun. 30, 2020	Jul. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Equity consideration issued in connection with acquisitions				$ 1,235,693	$ 6,248
Deferred payments				983	33
Contingent consideration liability				21,572	10,825		$ 33,540	$ 14,725
Estimated fair values of net assets acquired
Goodwill				3,231,200			$ 998,810
Cash receipt from working capital adjustment				558
Payment of contingent consideration					1,000
Significant Acquisitions In 2021 [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment				1,325,133
Equity consideration issued in connection with acquisitions				1,235,693
Deferred payments				983
Consideration paid allocated to contingent consideration				1,000
Total consideration				2,562,809
Estimated fair values of net assets acquired
Cash				31,944
Accounts receivable				97,523
Inventory				39,525
Prepaid and other current assets				4,828
Equipment and other fixed assets				179,761
Other assets				1,194
Identifiable intangible assets				142,000
Goodwill				2,254,990
Deferred tax liability				(63,222)
Accounts payable and accrued expenses				(96,325)
Contract liabilities				(14,583)
Net liabilities - working capital				(11,576)
Other long-term liabilities				(1,055)
Capital lease obligations				(2,195)
Net assets acquired				2,562,809
AeroCare Holdings [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment	$ 1,100,000
Interest acquired, as a percent	100.00%
Estimated fair values of net assets acquired
Cash	$ 27,700
Accounts receivable	75,900
Inventory	27,600
Equipment and other fixed assets	163,500
Identifiable intangible assets	138,200
Goodwill	2,100
Deferred tax liability	(63,700)
Accounts payable and accrued expenses	(82,700)
Net liabilities - working capital	(20,900)
AeroCare Holdings [Member] | Tradenames [Member]
Estimated fair values of net assets acquired
Identifiable intangible assets	$ 68,200
Other
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment				4,900
Deferred payments				1,000
Estimated fair values of net assets acquired
Accounts receivable				400
Inventory				200
Equipment and other fixed assets				700
Goodwill				4,900
Accounts payable and accrued expenses				(200)
Net liabilities - working capital				(100)
Significant Acquisitions In 2020 [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment					108,199
Equity consideration issued in connection with acquisitions					6,248
Deferred payments					33
Total consideration					114,480
Estimated fair values of net assets acquired
Cash					736
Accounts receivable					20,118
Inventory					4,413
Prepaid and other current assets					1,334
Equipment and other fixed assets					25,264
Goodwill					76,060
Accounts payable and accrued expenses					(6,493)
Contract liabilities					(3,906)
Unfavorable lease liability					(1,419)
Capital lease obligations					(1,627)
Net assets acquired					114,480
Cash receipt from working capital adjustment				600
Patient Care Solutions (PCS) [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment			$ 15,000
Interest acquired, as a percent			100.00%
Estimated fair values of net assets acquired
Accounts receivable					16,300
Equipment and other fixed assets					500
Goodwill					1,400
Net liabilities - working capital					(3,200)
Advanced Home Care Inc [Member]
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash payment		$ 58,500
Maximum potential contingent consideration				5,000	9,000	$ 5,000
Estimated fair values of net assets acquired
Net assets - working capital					500
Equipment and other fixed assets					18,400
Goodwill					$ 39,600
Solara Medical Supplies, LLC [Member]
Estimated fair values of net assets acquired
Cash receipt from working capital adjustment				$ 600

Acquisitions - Pro-forma Financ

Acquisitions - Pro-forma Financial Information and Results of Business Acquired (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Pro-forma financial information:
Pro-forma net revenue	$ 631,568	$ 572,298	$ 1,224,287	$ 1,102,997
Pro-forma operating income	66,964	55,719	92,600	96,957
Net revenue since acquisition date	248,209	53,002	390,856	93,727
Operating income (loss) since acquisition date	$ 37,306	$ (2,061)	$ 57,689	$ (7,621)

Equipment and Other Fixed Ass_3

Equipment and Other Fixed Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 443,758	$ 192,417
Less accumulated depreciation	(134,687)	(81,949)
Equipment and other fixed assets, net	309,071	110,468
Patient medical equipment
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	379,683	158,108
Delivery vehicles
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	21,666	8,211
Other
Property, Plant and Equipment [Line Items]
Equipment and other fixed assets, gross	$ 42,409	$ 26,098

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and post-closing adjustments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net carrying amount
Beginning balance			$ 998,810,000
Acquired goodwill during the period			2,254,990,000
Net cash receipts relating to prior acquisition			(558,000)
Increase (reduction)			(22,042,000)
Ending balance	$ 3,231,200,000		3,231,200,000
Goodwill, Impairment Loss	$ 0	$ 0	0	$ 0
Solara Medical Supplies, LLC [Member]
Net carrying amount
Net cash receipts relating to prior acquisition			(600,000)
Increase to accounts receivable			28,900,000
Increase to accounts payable			6,300,000
Decrease to goodwill from post-closing adjustment			$ 22,600,000

Goodwill and Identifiable Intan

Goodwill and Identifiable Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 13,900	$ 0	$ 24,231	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
2022	55,876		55,876
2023	41,293		41,293
2024	20,876		20,876
2025	20,817		20,817
2026	18,720		18,720
Thereafter	76,048		76,048
Finite-Lived Intangible Assets, Net, Total	233,630		233,630		$ 116,061
Impairment of Intangible Assets, Finite-lived	0	$ 0	0	$ 0
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	6,711		$ 6,711		$ 1,793
Finite-Lived Intangible Assets, Remaining Amortization Period			9 years 2 months 12 days		8 years 9 months 18 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	98,889		$ 98,889		$ 32,007
Payor contracts
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	7,716		$ 7,716		$ 3,616
Finite-Lived Intangible Assets, Remaining Amortization Period			9 years 1 month 6 days		9 years 7 months 6 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	74,284		$ 74,284		$ 78,384
Contractual rental agreements
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	14,583		$ 14,583
Finite-Lived Intangible Assets, Remaining Amortization Period			1 year 9 months 18 days
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	55,417		$ 55,417
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	1,260		$ 1,260		$ 630
Finite-Lived Intangible Assets, Remaining Amortization Period			4 years		4 years 6 months
Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]
Finite-Lived Intangible Assets, Net, Total	$ 5,040		$ 5,040		$ 5,670

Fair Value of Assets and Liab_3

Fair Value of Assets and Liabilities - Valuation of Financial Assets and Liabilities (Details) - Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Level 1
Assets
Total assets measured at fair value	$ 58	$ 5,602
Level 1 | Money market accounts
Assets
Total assets measured at fair value	58	5,602
Level 2
Liabilities
Total liabilities measured at fair value	12,178	16,161
Level 2 | Interest Rate Swap Short-term [Member]
Liabilities
Total liabilities measured at fair value	5,938	5,941
Level 2 | Interest Rate Swap Long-term [Member]
Liabilities
Total liabilities measured at fair value	6,240	10,220
Level 3
Liabilities
Total liabilities measured at fair value	141,288	217,922
Level 3 | Acquisition-related contingent consideration obligations-short term
Liabilities
Total liabilities measured at fair value	20,004	23,941
Level 3 | Acquisition-related contingent consideration obligations-long term
Liabilities
Total liabilities measured at fair value	1,568	9,599
Level 3 | Contingent consideration common shares liability-short term
Liabilities
Total liabilities measured at fair value	25,758	36,846
Level 3 | Contingent consideration common shares liability-long term
Liabilities
Total liabilities measured at fair value	20,675	33,631
Level 3 | Warrant Liability Noncurrent [Member]
Liabilities
Total liabilities measured at fair value	$ 73,283	$ 113,905

Fair Value - Contingent Conside

Fair Value - Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	$ 33,540	$ 14,725
Additions	1,000
Payments	(13,396)	(1,000)
Gain	255	(2,900)
Other activity	173
Contingent consideration liability at end of period	21,572	$ 10,825
Level 3 | Other current liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	23,900
Contingent consideration liability at end of period	20,000
Level 3 | Other long-term liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration liability at beginning of period	9,600
Contingent consideration liability at end of period	$ 1,600

Fair Value of Assets and Liab_4

Fair Value of Assets and Liabilities - Non-financial Assets Measured on Non-recurring Basis (Details) - Nonrecurring - Level 3 - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill (annual impairment assessment)	$ 3,231,200	$ 998,810
Finite-lived Intangible Assets, Fair Value Disclosure	$ 233,630	$ 116,061

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Financial instruments (Details) - Derivatives designated as hedging instruments - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Derivative financial instruments
Fair Value Liability	$ (12,178)	$ (16,161)
Interest rate swap agreements
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional amount	250,000	250,000
Interest rate swap agreements | Other current liabilities
Derivative financial instruments
Fair Value Liability	(5,938)	(5,941)
Interest rate swap agreements | Other long-term liabilities
Derivative financial instruments
Fair Value Liability	$ (6,240)	$ (10,220)

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Effect on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income	$ 0.7	$ 0.7	$ 1.4	$ 1.4
Derivatives in cash flow hedging relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative	$ 1.4	$ (0.4)	$ 4	$ (11.1)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts Payable and Accrued Expenses
Accounts payable	$ 260,580	$ 191,038
Employee related accruals	42,854	26,705
Accrued interest	24,974	11,062
Other	22,306	25,407
Accounts payable and accrued expenses	$ 350,714	$ 254,212

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt, Net	$ 1,873,076	$ 784,714
Current portion	(96,750)	(8,146)
Long-term portion	1,776,326	776,568
Revolving Credit Loans 2021 [Member]
Debt Instrument [Line Items]
Debt, Gross	175,000
Term Loan 2021 [Member]
Debt Instrument [Line Items]
Debt, Gross	800,000
Revolving Credit Loans 2020
Debt Instrument [Line Items]
Debt, Gross		55,000
Term Loan 2020
Debt Instrument [Line Items]
Debt, Gross		248,438
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]
Debt Instrument [Line Items]
Debt, Gross	850,000
Senior Notes 6.125 Percent Due 2028 [Member]
Debt Instrument [Line Items]
Debt, Gross		350,000
New Promissory Note
Debt Instrument [Line Items]
Debt, Gross	$ 71,750	143,500
Other
Debt Instrument [Line Items]
Debt, Gross		$ 333

Debt - Credit Facilities (Detai

Debt - Credit Facilities (Details) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 31, 2020

Nov. 30, 2019

Jun. 30, 2021

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Apr. 30, 2021

Jan. 20, 2021

Jan. 04, 2021

Dec. 31, 2020

Nov. 08, 2019

Mar. 31, 2019

Debt Instrument [Line Items]

Write-off of deferred financing costs

$ 3,495

Proceeds from Lines of Credit

1,070,000

$ 70,000

Repayment of loan

470,521

$ 21,641

Credit Agreement 2021 [Member]

Debt Instrument [Line Items]

Payments of Debt Issuance Costs

7,600

Write-off of deferred financing costs

$ 2,100

2,100

Letters of credit outstanding

$ 14,900

$ 14,900

Credit Agreement 2021 [Member] | Previously Reported [Member]

Debt Instrument [Line Items]

Write-off of deferred financing costs

$ 4,200

Credit Agreement 2021 [Member] | Minimum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.25%

Credit Agreement 2021 [Member] | Maximum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.50%

Credit Agreement 2021 [Member] | LIBOR | Minimum

Debt Instrument [Line Items]

Rate margin (as a percent)

1.50%

Credit Agreement 2021 [Member] | LIBOR | Maximum

Debt Instrument [Line Items]

Rate margin (as a percent)

3.25%

Revolving Credit Loans 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 450,000

Proceeds from Lines of Credit

$ 270,000

Debt balance outstanding

175,000

175,000

Revolver balance

$ 175,000

$ 175,000

Credit facility Interest rate

2.13%

2.13%

Remaining maximum borrowings available

$ 260,100

$ 260,100

Letter Of Credit 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 55,000

Term Loan 2021 [Member]

Debt Instrument [Line Items]

Borrowing capacity

$ 800,000

Debt balance outstanding

$ 800,000

$ 800,000

Credit facility Interest rate

2.13%

2.13%

Term Loan 2021 [Member] | First Specified Repayment Period [Member]

Debt Instrument [Line Items]

Quarterly principal repayments

$ 5,000

Term Loan 2021 [Member] | Second Specified Repayment Period [Member]

Debt Instrument [Line Items]

Quarterly principal repayments

10,000

Revolving Credit Loans 2020

Debt Instrument [Line Items]

Borrowing capacity

$ 200,000

Debt balance outstanding

$ 55,000

Revolving Credit Loans 2020 | Minimum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.25%

Revolving Credit Loans 2020 | Maximum

Debt Instrument [Line Items]

Commitment fee (as a percent)

0.50%

Term Loan 2020

Debt Instrument [Line Items]

Borrowing capacity

$ 250,000

Debt balance outstanding

248,438

Term Loan 2020 | LIBOR | Minimum

Debt Instrument [Line Items]

Rate margin (as a percent)

2.50%

Term Loan 2020 | LIBOR | Maximum

Debt Instrument [Line Items]

Rate margin (as a percent)

3.75%

Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]

Debt Instrument [Line Items]

Face amount

$ 500,000

Debt balance outstanding

$ 850,000

850,000

Debt Interest rate

4.625%

Senior Notes 6.125 Percent Due 2028 [Member]

Debt Instrument [Line Items]

Face amount

$ 350,000

Debt balance outstanding

350,000

Debt Interest rate

6.125%

New Promissory Note

Debt Instrument [Line Items]

Write-off of deferred financing costs

1,400

1,400

Debt balance outstanding

$ 71,750

$ 71,750

143,500

Promissory Note With Investor [Member]

Debt Instrument [Line Items]

Face amount

$ 100,000

$ 100,000

Promissory Note From Members Interest [Member]

Debt Instrument [Line Items]

Face amount

$ 43,500

Other

Debt Instrument [Line Items]

Debt balance outstanding

$ 333

2019 Credit Facility

Debt Instrument [Line Items]

Borrowing capacity

425,000

Proceeds from Lines of Credit

$ 216,300

Repayment of credit facility

$ 523,900

Initial/credit facility term loan

Debt Instrument [Line Items]

Borrowing capacity

300,000

Repayment of loan

$ 50,000

Delayed Draw Term Loan

Debt Instrument [Line Items]

Borrowing capacity

50,000

Revolving credit facility/revolver

Debt Instrument [Line Items]

Borrowing capacity

$ 75,000

Debt - Notes (Details)

Debt - Notes (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 04, 2021	Jul. 31, 2020	May 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Nov. 08, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Write-off of deferred financing costs						$ 3,495
Proceeds from the issuance of senior unsecured notes						500,000
Deferred financing costs				$ 23,674		23,674		$ 12,557
Loss on extinguishment of debt from prepayment penalty						8,454
Repayments of Long-term Debt						470,521	$ 21,641
Gain (loss) on extinguishment of debt						(8,454)
Number of shares in Consideration Unit			1
Number of shares under Put/Call Option and Consent Agreement								1,898,967
Minimum variable price, as percent of weighted average price								85.00%
Sales price (in dollars per share)								$ 15.76
Equity activity resulting from the Put/Call Agreement					$ (29,927)		$ (29,900)
Additional paid-in capital
Debt Instrument [Line Items]
Equity activity resulting from the Put/Call Agreement					$ (29,927)
Minimum
Debt Instrument [Line Items]
Minimum fixed purchase price (in dollars per share)								$ 14.50
New Promissory Note
Debt Instrument [Line Items]
Debt balance outstanding				71,750		71,750		$ 143,500
Write-off of deferred financing costs				1,400		1,400
Loss on extinguishment of debt from prepayment penalty				8,500		8,500
Gain (loss) on extinguishment of debt				$ (8,500)		$ (8,500)
New Promissory Note | Period starting on the closing date and ending on the seventh anniversary
Debt Instrument [Line Items]
Debt Interest rate				12.00%		12.00%
New Promissory Note | Period starting on the day after the seventh anniversary of the closing date and ending on the maturity date
Debt Instrument [Line Items]
Debt Interest rate				15.00%		15.00%
New Promissory Note | Scenario, Plan [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt from prepayment penalty						$ 7,200
Gain (loss) on extinguishment of debt						$ (7,200)
New Promissory Note | LIBOR | Period starting on the day after the seventh anniversary of the closing date and ending on the maturity date
Debt Instrument [Line Items]
Rate margin (as a percent)						12.00%
Promissory Note With Investor [Member]
Debt Instrument [Line Items]
Face amount									$ 100,000	$ 100,000
Promissory Note From Members Interest [Member]
Debt Instrument [Line Items]
Face amount									$ 43,500
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member]
Debt Instrument [Line Items]
Face amount	$ 500,000
Debt balance outstanding				$ 850,000		$ 850,000
Debt Interest rate	4.625%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed	40.00%
Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings	104.625%
Deferred financing costs	$ 10,400
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period One
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Two
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	102.313%
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Three
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.156%
Senior Unsecured Notes 4.625 Per Cent Due 2029 [Member] | Redemption Period Four
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Senior Notes 6.125 Percent Due 2028 [Member]
Debt Instrument [Line Items]
Face amount		$ 350,000
Debt balance outstanding								350,000
Debt Interest rate		6.125%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed		40.00%
Debt Instrument Redemption Price Percentage, Proceeds From Equity Offerings		106.125%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period One
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Two
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		103.063%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Three
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		102.042%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Four
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		101.021%
Senior Notes 6.125 Percent Due 2028 [Member] | Redemption Period Five and thereafter
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%
Other
Debt Instrument [Line Items]
Debt balance outstanding								$ 333

Stockholders' Equity - Activity

Stockholders' Equity - Activity (Details) $ / shares in Units, $ in Thousands	Mar. 18, 2021shares	Jan. 08, 2021USD ($)$ / sharesshares	Jan. 01, 2021shares	Nov. 08, 2019	Jun. 30, 2020$ / sharesshares	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Feb. 01, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Subsidiary or Equity Method Investee [Line Items]
Net proceeds | $							$ 278,850
Offering costs | $							13,832
Stock exchange ratio				1
Exchange of equity interests, in shares			13,218,758
Value of shares exchanged | $							$ 77,900
Preferred stock, par value (in dollars per share) | $ / shares							$ 0.0001			$ 0.0001
Debt repayment | $							$ 470,521	$ 21,641
Preferred stock, shares issued (in shares)							124,060			163,560
Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Percentage of economic and voting interests				49.00%
DFB Acquisitions Corp
Subsidiary or Equity Method Investee [Line Items]
Percentage of economic and voting interests				51.00%
Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Controlling interest, as a percent				56.00%
Adapt Health Holdings LLC | Shareholders of Adapt Health Holdings LLC
Subsidiary or Equity Method Investee [Line Items]
Noncontrolling interest, as a percent				44.00%
Class A Common Stock
Subsidiary or Equity Method Investee [Line Items]
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)					15,810,547		3,950,000
Conversion Of Series C-1 Preferred Stock To Class A Common Stock, Shares	13,047,473
Series B-1 Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)					158,105.47		39,500
Preferred stock, par value (in dollars per share) | $ / shares					$ 0.0001			$ 0.0001
Preferred stock, liquidation preference (in dollars per share) | $ / shares					$ 0.0001			$ 0.0001
Shares of common stock received in conversion for each share of preferred stock					100			100
Preferred stock conversion, ceiling as a percent of outstanding common stock					4.9
Series C Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, liquidation preference (in dollars per share) | $ / shares									$ 0.0001
Shares of common stock received in conversion for each share of preferred stock	100
Series C Preferred Stock [Member] | AeroCare Holdings [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, shares issued (in shares)									130,474.73
Public Offering [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares issued		8,450,000
Share Price | $ / shares		$ 33
Proceeds from sale of stock | $		$ 278,900				$ 265,018
Net proceeds | $		265,600
Offering costs | $		$ 13,800				$ 13,832

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Nov. 08, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants outstanding	4,280,548			4,280,548		12,666,666
Common stock for each warrant exercised						1
Warrant exercisable price						$ 11.50
Warrants exercised in cashless transaction, number exercised		8,386,118
Warrant liability, beginning		$ 113,905		$ 113,905	$ 27,635
Change in fair value of warrant liability	$ (37,454)		$ (654)	(40,622)	35,446
Reclassification of warrant liability to equity for exercised warrants					(21,019)
Warrant liability, ending	$ 73,283		$ 42,062	$ 73,283	42,062
Proceeds from exercise of warrants					$ 11,883

Stockholders' Equity - Continge

Stockholders' Equity - Contingent consideration (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Earn-out consideration, shares per annual installment					1
First stock price hurdle (in dollars per share)					$ 15
Second stock price hurdle (in dollars per share)					18
Third stock price hurdle (in dollars per share)					$ 22
Earn-out consideration, number of shares issued during the period					1
Change in amount of contingent common share liability
Contingent consideration common shares liability	$ 46,433	$ 25,641	$ 46,433	$ 25,641	$ 70,477	$ 9,316
Change in fair value of contingent consideration - common shares liability	(22,079)	$ (42)	(24,044)	$ 16,325
Contingent consideration common shares liability	25,758		25,758		36,846
Contingent Consideration Liability, Earn-Out, Current	25,758		25,758		36,846
Long term portion of contingent consideration common shares liability	$ 20,675		$ 20,675		$ 33,631
Minimum
Class of Stock [Line Items]
Actual average share price during the period					$ 15
Class A Common Stock
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001		0.0001
Class B Common Stock
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001		$ 0.0001

Stockholders' Equity - Compensa

Stockholders' Equity - Compensation, options grants and assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 27, 2021	Apr. 13, 2021	Jan. 31, 2021	Jun. 30, 2021	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted			703,170		703,000
Options granted, exercise price					$ 48.72
Options granted, grant date fair value			$ 6,900
Options forfeited		648,401		234,390	914,000
Exercise of stock options (in shares)				200,000	216,000
Exercise of stock options				$ 2,300
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Exercise period			5 years
Accelerated vesting, number of shares		184,932
Accelerated vesting cost				$ 1,900	$ 1,900
Expected volatility					44.50%
Risk-free interest rate					0.18%
Expected term					4 years
2019 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance				8,000,000	8,000,000
Stock available for issuance				1,573,266	1,573,266
2019 Incentive Plan | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance	10,000,000
Additional shares authorized for issuance	2,000,000

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option activity (Details) - $ / shares	Apr. 13, 2021	Jan. 31, 2021	Jun. 30, 2021	Jun. 30, 2021
Number of Options
Outstanding at beginning of period (in shares)		3,464,000		3,464,000
Granted (in shares)		703,170		703,000
Exercised (in shares)			(200,000)	(216,000)
Forfeited (in shares)	(648,401)		(234,390)	(914,000)
Outstanding at end of period (in shares)			3,037,000	3,037,000
Weighted-Average Grant Date Fair Value per Share
Outstanding at beginning of period (in dollars per share)		$ 2.18		$ 2.18
Granted (in dollars per share)				9.81
Exercised (in dollars per share)				2.43
Forfeited (in dollars per share)				6.34
Outstanding at end of period (in dollars per share)			$ 3.31	3.31
Weighted-Average Exercise Price per Share
Outstanding at beginning of period (in dollars per share)		$ 11.56		11.56
Granted (in dollars per share)				48.72
Exercised (in dollars per share)				11.85
Forfeited (in dollars per share)				11.66
Outstanding at end of period (in dollars per share)			$ 17.25	$ 17.25
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)				7 years 9 months 18 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense		$ 7.4	$ 3.3	$ 16	$ 5.5
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				812,000
Vesting accelerated, shares		22,192
Vested fair value		$ 0.5		$ 0.5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance at beginning of period				2,248,000
Granted, shares				812,000
Vested, shares				(156,000)
Forfeited, shares		(77,808)		(568,000)
Non-vested balance at end of period		2,336,000		2,336,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, grant date fair value at beginning of period				$ 15.60
Granted, grant date fair value				32.10
Vested, grant date fair value				13.79
Forfeited, grant date fair value				16.49
Non-vested, grant date fair value at end of period		$ 21.27		$ 21.27
Restricted Stock | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				808,115
Grant date fair value				$ 25.9
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares				808,115
Restricted Stock | Non-employee Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares				4,285
Vesting period				1 year
Grant date fair value				$ 0.1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted, shares				4,285
Restricted Stock | Minimum | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
Restricted Stock | Maximum | Various Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
Vesting based on service (continued employment)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Vesting percentage	25.00%					50.00%
Vesting based on performance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						1 year
Vesting percentage						50.00%

Stockholders' Equity - Incentiv

Stockholders' Equity - Incentive units (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended	12 Months Ended
	May 31, 2020	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2018
Vesting based on service (continued employment)
Equitybased Compensation
Vesting percentage	25.00%		50.00%
Vesting period			4 years
Accelerated vesting cost		$ 1.5
Vesting based on performance
Equitybased Compensation
Vesting percentage			50.00%
Vesting period			1 year
2019 Incentive Plan
Equitybased Compensation
Grant date fair value			$ 4.5
2018 Incentive Plan
Equitybased Compensation
Grant date fair value				$ 5.3

Stockholders' Equity - Other ac

Stockholders' Equity - Other activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 7.4	$ 3.3	$ 16	$ 5.5
Awards To Newly Hired Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, shares			53,249
Equity-based compensation expense			$ 2

Stockholders' Equity - Equity-b

Stockholders' Equity - Equity-based compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 7.4	$ 3.3	$ 16	$ 5.5
Unrecognized compensation expense	39.3		$ 39.3
Recognition period			2 years 10 months 24 days
General and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	5.7	1.6	$ 11.1	3.3
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 1.7	$ 1.7	$ 4.9	$ 2.2
2019 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock available for issuance	1,573,266		1,573,266

Earning Per Share (Details)

Earning Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net Income (Loss) Attributable to Parent [Abstract]
Net Income (Loss) Attributable to Parent	$ 79,107	$ 4,470	$ 75,141	$ (30,081)
Earnings allocated to participating securities	6,908	119	7,431
Net income (loss) basic	72,199	4,351	67,710	(30,081)
Change in fair value of contingent consideration - common shares liability, net of tax	(18,357)	(42)	(19,991)
Change in fair value of warrant liability	37,454	654	40,622	(35,446)
Net Income (Loss) Available to Common Stockholders, Diluted	$ 16,388	$ 3,655	$ 7,097	$ (30,081)
Denominator:
Weighted Average Number of Shares Outstanding, Basic	129,664	44,508	120,438	43,242
Add: Contingent Consideration Shares	2,000	350	2,000
Add: Warrants	2,554	2,400	2,736
Diluted weighted average common shares outstanding	136,582	47,834	127,720	43,242
Earnings Per Share, Basic	$ 0.56	$ 0.10	$ 0.56	$ (0.70)
Earnings Per Share, Diluted	$ 0.12	$ 0.08	$ 0.06	$ (0.70)
Anti-dilutive securities excluded (in shares)	12,406	2,296	13,217	4,349
Preferred Stock
Denominator:
Anti-dilutive securities excluded (in shares)	12,406	1,216	13,217	608
Options
Denominator:
Add: Stock options	1,533		1,641
Anti-dilutive securities excluded (in shares)		1,080		883
Restricted Stock
Denominator:
Add: Unvested restricted stock	831	576	905
Anti-dilutive securities excluded (in shares)				548
Warrant [Member]
Denominator:
Anti-dilutive securities excluded (in shares)				1,960
Contingent Consideration Common Shares [Member]
Denominator:
Anti-dilutive securities excluded (in shares)				350

Leases - Capital (Details)

Leases - Capital (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Capital Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
2022	$ 24,052		$ 24,052
2023	269		269
2024	22		22
Future annual minimum payments required under lease obligations
Total	24,343		24,343
Less amount representing interest	(122)		(122)
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Total	24,221		24,221
Current portion	(23,919)		(23,919)		$ (22,282)
Noncurrent	302		302
Equipment under capital leases
Equipment under capital leases
Cost of equipment under capital leases	40,400		40,400		43,300
Accumulated depreciation of equipment under capital leases	12,100		12,100		$ 13,000
Maximum
Capital Leased Assets [Line Items]
Interest expense related to capital leases	$ 100	$ 100	$ 100	$ 100

Lease - Operating (Details)

Lease - Operating (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Lease Commitments
Deferred rent	$ 1,400		$ 1,400		$ 1,400
Rent expense	9,100	$ 3,800	17,000	$ 7,300
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
2022	31,212		31,212
2023	25,466		25,466
2024	18,244		18,244
2025	11,274		11,274
2026	6,720		6,720
Thereafter	13,978		13,978
Minimum annual lease commitments under noncancelable leases
Lease commitments	106,894		106,894
Minimum sublease rentals	$ 3,200		$ 3,200

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Taxes
Income Tax Expense (Benefit)	$ 12,330	$ 1,826	$ 10,635	$ 185
Unrecognized tax benefits	$ 1,900		1,900		$ 1,900
Increase in liability due to additional exchanges			146,500
Increase in deferred tax asset			163,300
Liability related to TRA			$ 300,100		$ 152,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended
	May 31, 2018item
Commitments and Contingencies.
Number of subsidiaries	1
Agreement Term	5 years

Related Party Transactions (Det

Related Party Transactions (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)item	Jun. 30, 2020USD ($)
Related Party Transaction [Line Items]
Gain (loss) on extinguishment of debt			$ (8,454)
Vendor two
Related Party Transaction [Line Items]
Number of executives | item			1
Ownership interest, as a percent	1.00%		1.00%
Expense for related party	$ 1,200	$ 600	$ 2,200	$ 1,100

Subsequent Events (Details)

Subsequent Events (Details) - Other - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Jul. 31, 2021	Jun. 30, 2021
Subsequent Event
Cash payment		$ 4.9
Subsequent Event
Subsequent Event
Cash payment	$ 124.4
Issuance of stock for acquisitions (in shares)	976,819